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ABSTRACT 
Alzheimer's disease (AD) is the most common dementing disease and the number of patients 
with AD is increasing as the population is ages. AD not only has a devastating effect on individual 
patients and their families, but it also poses an enormous socioeconomic burden to society. AD is a 
disease that develops slowly over a time range of two decades before the appearance of first 
symptoms. The neuropathology starts to develop during the preclinical period of the disease, so that at 
first symptomatic stage the pathology is already advanced. This is a major obstacle in treating the 
disease because at present there is no way known to repair nerve damage once it has occurred. 
Previous studies indicated that levels of CSF biomarkers Aβ42, tau and phospho-tau are altered in AD 
patients in comparison to healthy controls or patients with other neurological diseases and they can be 
used as a diagnostic aid, especially in clinically challenging conditions, for example in the 
differentiation between mild AD and depression. 
At the beginning of this study, little was known about these biomarkers before the onset of 
clinical AD. Since AD neuropathology starts to develop decades before symptoms, the original 
hypothesis was that AD associated changes in CSF biomarkers could be detected before the 
appearance of clinical AD. The main aim of the study was to examine whether these changes would 
predict the development of AD in patients with mild cognitive impairment (MCI) who have a high risk 
for of suffering AD within a period of a few years. The association between AD associated 
pathological changes in brain and the CSF biomarker levels were also examined. 
The results of this study revealed that the AD associated changes in CSF biomarkers, i.e. 
decrease in Aβ42 and increase in tau and phospho-tau occurred during the predementia stage of AD 
before the clinical AD diagnosis. CSF Aβ42, tau and phospho-tau values were also associated with 
medial temporal lobe atrophy. The combination of decreased CSF Aβ42 and increased tau or phospho-
tau could differentiate MCI patients who would develop AD from those who remained stable with 
high specificity even several years before the clinical diagnosis of AD. These results suggest that the 
abnormal CSF biomarker levels can be used for confirmation of a clinical diagnosis of possible early 
AD. However, the sensitivity was low and therefore a negative result cannot exclude presence of AD. 
A large proportion of MCI patients did not exhibit memory impairment. Executive dysfunction 
without amnestic symptoms was common, and these patients developed AD almost as frequently as 
MCI patients with memory impairment.  
In conclusion, the pathological changes of the biomarker levels occur early during the course of 
the disease, and can predict development of AD in patients with cognitive impairment. In the clinical 
context, patients with cognitive impairment without memory complaint should also be considered to 
be at high risk for developing AD.  
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To dare is to lose one's footing momentarily. 
To not dare is to lose oneself. 
 
-Soren Kierkegaard-
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1. INTRODUCTION 
 
The proportion of the elderly is growing steadily as the longevity of the population increases. 
This leads to greater numbers of patients suffering age-associated neurodegenerative diseases, 
including dementia. Dementia not only has a devastating effect on the individual patients and 
their families but it also imposes enormous socioeconomic burden on society. It is estimated 
that in 2005 there were over 29 million patients with dementia and the worldwide societal 
costs of dementia were US$315 billion (Wimo et al. 2007). Over half of the dementia cases 
are caused by Alzheimer's disease (AD). As the treatments for AD evolve, it will become 
increasingly important to diagnose AD patients as early and as accurately as possible. 
 
Diagnosis of possible or probable AD is based on the clinical criteria and exclusion of other 
possible causes for dementia. The criteria include an insidious onset and progressive 
impairment in memory and other cognitive functions severe enough to cause a dementia 
syndrome. This is a significant problem, since AD has a preclinical period which may last 
over two decades. At the time of diagnosis using current criteria, the AD associated 
neuropathology is already well advanced. Therefore the focus of research on AD diagnostics 
has shifted to the time when the patient exhibits the first clinical symptoms of the disease, 
usually memory impairment, but the symptoms are not severe enough to validate a diagnosis 
of AD. These studies led to development of the concept of mild cognitive impairment (MCI), 
which refers to a transitional stage between cognitively healthy individuals to patients with 
clinically diagnosable AD (Flicker et al. 1991). Numerous different diagnostic criteria for 
MCI have been suggested, but it has become evident that MCI patients represent a very 
heterogeneous group with different etiologies and prognoses.  
 
A definite diagnosis of AD requires a post mortem neuropathological examination of brain. 
The neuropathological hallmarks of AD include the neurofibrillary tangles (NFT) consisting 
of hyperphosphorylated tau protein and amyloid plaques consisting of amyloid-beta (Aβ) 
peptide. At the advanced stage of AD, the clinical diagnosis is relatively accurate, but the 
early diagnosis of AD is challenging. AD associated pathology is also common in patients 
with other dementing diseases. It is difficult to identify patients with mixed pathology using 
the current clinical methods. The hypothesis was that since both Aβ and tau can be detected in 
CSF these proteins hold potential significance as biomarkers for AD. After numerous studies 
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determining the levels of Aβ42 (the more amyloidogenic form of Aβ), tau and 
hyperphosphorylated tau (phospho-tau) in AD patients and comparing these values with 
healthy controls and patients with other neurological diseases, it became evident that CSF 
levels of Aβ42 are decreased whereas those of tau and phospho-tau are increased in AD 
(Blennow and Hampel 2003).  
 
Even though the CSF Aβ42, tau and phospho-tau were established as the most promising 
biomarkers for AD, there were still many unanswered questions. Most studies have been 
cross-sectional studies performed in clinical patient series. Therefore the actual association 
between the neuropathologically confirmed diagnosis and CSF biomarkers was uncertain. 
Also the mechanisms responsible for the changes in CSF and the association between other 
AD associated pathological changes for example medial temporal lobe (MTL) atrophy were 
unclear. Furthermore, the AD patients in these studies had relatively advanced disease and 
there was no data available on CSF Aβ42, tau and phospho-tau from the preclinical period of 
AD. A few small studies including MCI patients had been published, but the heterogeneity of 
MCI complicates the interpretation of the results of cross-sectional studies. In addition, the 
follow-up period needs to be several years to reliably detect those MCI patients who develop 
AD. In this context the present series of studies was initiated, to study the predictive value of 
CSF biomarkers for the development of dementia in patients with MCI and to examine the 
association between the CSF biomarkers and AD associated pathological changes. 
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2. REVIEW OF THE LITERATURE 
 
2.1 ALZHEIMER'S DISEASE IS A STAGE CONCURRENT DISORDER 
When Alois Alzheimer described his patient, Auguste D, about 100 years ago, the syndrome 
that was later named AD was thought to be a rare disease causing presenile dementia. 
Subsequently, it was revealed that AD is in fact the most common form of dementia, 
responsible for over half of all dementia cases. The rare early onset AD is caused by dominant 
mutations and this form runs in families, whereas in most of the cases, the onset of the disease 
occurs later, after the age of 65 years. There are genetic risk factors also for late onset AD but 
the late onset AD genes are not causative factors, they only increase the risk for AD. 
 
Dementia is a syndrome that is defined by a decline in multiple cognitive domains so severe 
to cause impairment in functional abilities and difficulties in activities in daily living. These 
symptoms may be caused by different etiologies, but neuropsychiatric causes such as 
depression and delirium must be excluded. The diagnosis of dementia is currently based on 
DSM-IV (American Psychiatric Association 1994). AD is a slowly progressing disease that is 
currently diagnosed based on the clinical criteria proposed by the National Institute of 
Neurologic and Communicative Disorders and Stroke and Alzheimer's Disease and Related 
Disorders Association (NINCDS-ADRDA) (McKhann et al. 1984). The criteria include 
insidious onset, progressive impairment in memory and other cognitive functions plus 
exclusion of other possible causes for dementia. Clinical work up includes taking medical 
history and performing medical, neurological and neuropsychological examination. Routine 
blood tests are done to exclude some treatable causes of dementia, for example B12 vitamin 
deficiency. Brain imaging, usually CT scan, is done to exclude for example vascular disease 
and normal-pressure hydrocephalus. The objective of the clinical assessment is to exclude the 
possibility of clinical conditions other than AD. 
 
The final clinical diagnosis can be either possible or probable AD, since the definite AD 
diagnosis is made by histopathological analysis of brain tissue obtained either by biopsy or 
during autopsy. The neuropathological changes in AD brain include amyloid plaques and 
NFTs, accompanied by neuronal death and synaptic loss in the affected areas. The initial 
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neuropathological changes may occur as early as two decades before the onset of clinical 
symptoms (Selkoe 2001). 
 
2.1.1 Neuropathological changes 
2.1.1.1 Amyloid pathology 
The quintessential feature of AD pathology is the presence of amyloid plaques in the cortical 
areas of the brain. The main component of the amyloid plaques is Aβ peptide (Masters et al. 
1985). The Aβ peptide is a derivative of a larger cell membrane spanning protein, amyloid 
precursor protein (APP). The Aβ peptide is formed by sequential cleavages of the APP, and it 
occurs as peptides with different numbers of amino acid residues. The most extensively 
studied species of Aβ peptides are the peptides containing 40 (Aβ40) and 42 (Aβ42) amino 
acid residues. Both forms occur in amyloid plaques, but the Aβ42 is deemed to be more 
amyloidogenic and therefore more damaging to the brain. 
 
The formation of amyloid plaques is thought to be initiated by Aβ42 but subsequently also 
Aβ40 starts to accumulate (Iwatsubo et al. 1994). The diffuse plaques occur early in the 
course of the disease. They can be detected only by antibodies staining Aβ and they are not 
surrounded by other neuropathological changes. Dense amyloid plaques contain fibrillar Aβ 
and also several other proteins, for example apolipoprotein E (ApoE). They can be detected 
by stains that are used for all amyloids found in the body, for example thioflavin-S. The dense 
plaques are also associated with dystrophic neurites and inflammatory processes. 
 
The search for the AD causing gene was facilitated by the finding that patients with Down 
syndrome (DS), who have a third copy of chromosome 21, develop AD type amyloid 
pathology at an early age. This association located the APP gene into chromosome 21 and in 
time, it was characterised and mutations in the APP gene were confirmed to cause early onset 
AD (Goate et al. 1991). There are several isoforms of APP, but the main isoform found in 
neurones is APP695 and this includes the Aβ sequence. It has been suggested that there are 
physiological and pathological metabolic routes for APP. When APP is cleaved by α-
secretase, which cleaves APP from the middle of the Aβ sequence, production of Aβ peptide 
is prevented (Haass 2004). During the formation of Aβ peptide, the APP is cleaved by β- and 
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γ-secretases (Haass 2004, Vassar et al. 1999, Wolfe 2006). All of the currently known 
mutations that cause familial AD are found in the APP gene or the genes encoding presenilin 
1 or 2. The presenilin 1 and 2 are essential parts of the γ-secretase complex and are thus 
crucial in determining the length of the generated Aβ peptide (Wolfe 2006). All familial AD 
mutations, except the Arctic APP mutation, selectively increase the formation of Aβ42 and 
therefore may promote fibrillation of the Aβ into amyloid plaques (Scheuner et al. 1996). The 
Arctic mutation lowers secreted levels of both Aβ40 and Aβ42 (Nilsberth et al. 2001). The 
intracellular location of APP is altered so that the generated Aβ remains in the intracellular 
compartment and there is less available APP for production of secreted Aβ (Sahlin et al. 
2007). 
 
One proposed mechanism for development of AD neuropathology is the so-called amyloid 
cascade hypothesis (Hardy and Selkoe 2002). Not only the above mentioned findings but also 
the vast number of subsequent studies on APP metabolism in AD explains why this theory is 
the most popular (but not the only) mechanism to explain the primary pathogenesis of AD. 
The pathological cascade begins when some factor, for example a genetic risk factor, aging or 
an environmental factor, increases the formation of Aβ42 or decreases its clearance from the 
brain. Should the initiating factor be a causative dominant genetic mutation, then the Aβ42 
load increases rapidly and the onset of symptoms happens at an early age. In late onset, 
sporadic AD, the progression of the pathology is slower and the symptomatic stage is reached 
later. Surprisingly, it was revealed that neither Aβ itself nor the accumulated Aβ plaques were 
particularly toxic to neurones. Instead, Aβ becomes toxic only after monomeric Aβ 
accumulates into oligomers (Walsh et al. 2002). These oligomers then induce an 
immunological response and mediate oxidative stress and impair the function of the affected 
neurones. Once a threshold in the pathology is passed, neuronal dysfunction and loss cause 
the first cognitive symptoms. Recently, a specific oligomer that includes twelve Aβ42 units 
was found to be the main culprit in causing the toxic effects of Aβ in transgenic mice (Lesne 
et al. 2006). If this finding is corroborated by studies on humans, this might offer a new target 
molecule for both diagnosis and treatment of AD. The significance of intracellular Aβ in the 
pathological process is somewhat unclear, but it is possible that it also contributes to the 
pathology. 
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2.1.1.2 Tau pathology 
In neurones, the tremendous length of the axon when compared to cell body complicates the 
maintenance of normal function of synapse. Therefore, neurones have very sophisticated 
machinery to guarantee a functional gateway between the body and periphery of the cell. This 
consists of microtubules that run along the axon and several different proteins that are 
involved in the trafficking of essential particles from the cell body to the synapse and back 
from synapse to body. These particles include cell organelles such as mitochondria and 
vesicles containing proteins derived from golgi, e.g. tau is one of these microtubule-
associated proteins. The main function of tau is to stabilize the microtubules in axons but it 
also reduces binding of a motor protein called kinesin to microtubules, which in turn obstructs 
axonal transport (Ebneth et al. 1998). Impaired axonal transport by tau hinders the growth of 
the neurites and makes them more vulnerable to oxidative stress (Stamer et al. 2002). These 
conflicting effects of tau on the wellbeing of neurone mean that tau is a metabolically 
dynamic protein. Under normal conditions, tau is constantly being phosphorylated and 
dephosphorylated and there is a physiological equilibrium between these two processes. 
 
Tau is expressed in several isoforms of different lengths (Goedert et al. 1989). 
Phosphorylation of tau is possible at 79 serine and threonine residues, at least thirty of which 
have been shown to be associated with abnormal phosphorylation in AD (Gong et al. 2005). 
Phosphorylation of tau inhibits its binding to microtubules and hyperphosphorylation of tau 
makes it neurotoxic (Fath et al. 2002). Hyperphosphorylated tau is also more resistant to 
proteases and this makes it more prone to aggregate (Alonso et al. 2001, Johnson et al. 1989). 
Eventually, hyperphosphorylated tau forms intraneuronal bundles of fibrils called paired 
helical filaments (Grundke-Iqbal et al. 1986) and after the affected neurone dies, only NFTs 
are left behind and the second characteristic hallmark of AD neuropathology has been 
generated. 
 
NFT pathology in the brain occurs in a well documented sequential manner (Braak and Braak 
1991). The first changes can be seen in entorhinal cortex (EC) and at that stage the patients do 
not have any cognitive impairment. When the disease progresses to a stage at which the 
patient starts to exhibit cognitive impairment, the pathology has spread to hippocampus (HC). 
Later on, the density of NFTs in these areas increases and the pathology spreads to amygdala 
and limbic nuclei of the thalamus. Finally, the pathology can be detected in neocortical areas 
and at this point the patients usually fulfil the clinical criteria for AD. The progression in the 
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pathology is accompanied by loss of cholinergic neurones in a similar sequential manner. The 
loss of cholinergic innervation starts from MTL, progresses to adjacent limbic areas and 
finally to cerebral cortex (Mesulam 2004). 
 
There has been an intense debate about which of these pathological processes, amyloid or tau 
associated neuropathology, is the initiator of AD pathology. The amyloid cascade hypothesis 
states that Aβ42 oligomerization and accumulation occur first, and the tau pathology and 
neuronal dysfunction are downstream events. Previous studies have shown that Aβ 
accumulation induces phosphorylation of tau (Alvarez et al. 1999) and mice carrying both 
mutant tau and APP develop more abundant NFT pathology in those brain areas that express 
both APP and tau in comparison to those areas which express only tau (Lewis et al. 2001). 
Furhermore, the injection of Aβ fibrils into the brains of mutant tau transgenic mice induces 
the formation of NFTs (Götz et al. 2001). Support for the hypothesis also includes the fact 
that all dominant mutations that cause AD are found in genes that are associated with APP 
metabolism (Haass 2004) whereas a mutation in the tau gene causes frontotemporal dementia 
(FTD) with parkinsonism, not AD (Hutton et al. 1998, Poorkaj et al. 1998, Spillantini et al. 
1998). Moreover, in one FAD patient, amyloid pathology was shown to appear before NFTs 
(Smith et al. 2001). Patients with the tau mutation display severe NFT pathology and 
cognitive impairment, but do not exhibit amyloid plaques. These findings indicate that 
pathological changes in tau are not alone sufficient enough to provoke amyloid pathology. 
Furthermore, PS1, which is linked to amyloid pathology, may also protect tau from 
hyperphosphorylation, and therefore PS1 mutations may promote AD pathology also through 
tau (Baki et al. 2004). A PS1 mutation can also cause tauopathy without the presence of 
amyloid plaques (Dermaut et al. 2004). Another serious argument against the amyloid cascade 
hypothesis is the classical staging of AD neuropathology depicted by Braak & Braak, which 
states that NFT pathology precedes cortical amyloid pathology and the extent of NFT 
pathology correlates better with the gradual cognitive impairment (Braak and Braak 1991). 
However, NFTs may develop as part of the normal aging since they are found in all aged 
individuals regardless of their cognitive status (Price and Morris 1999). However, not only 
NFTs but also amyloid pathology can be detected in many asymptomatic elderly subjects 
(Bennett et al. 2006, Galvin et al. 2005, Neuropathology Group. Medical Research Council 
Cognitive Function and Aging Study 2001). 
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2.1.2 Clinical symptoms 
When AD was first described, it was thought to be a rare condition that affected only a small 
number of relatively young patients. The cognitive impairment of the elderly was considered 
to be part of the normal aging process, caused by atherosclerosis of brain arteries. Later on, 
the neuropathological studies changed that view by revealing that AD associated pathology 
was a common feature in the elderly (Tomlinson et al. 1968). Although the onset of dementia 
varied greatly, the early onset and late onset dementia were considered to represent the same 
disease with uniform pathology. 
 
From the diagnostic perspective this classification presents some difficulties. In early onset 
AD, the symptoms appear at an early age and usually progress quickly. This form of the 
disease is relatively easy to diagnose, because the symptoms are so distinct from most other 
diseases occurring at that age. However, in late onset AD, the symptoms develop later and 
progression is much slower. The pathological process of AD may begin as much as two 
decades before the clinical symptoms. During this preclinical period, it is not possible to 
detect patients who have AD pathology in their brain even with the most sophisticated 
neuropsychological tests (Driscoll et al. 2006). Even when the first cognitive symptoms 
occur, detecting the patients who have these symptoms due to AD is difficult because of the 
very insidious onset of symptoms. Similar symptoms may also be evoked by other causes 
such as depression or they can be regarded as normal cognitive changes associated with 
aging. 
 
The salient feature of AD is the impairment in episodic memory, which is usually the first 
clinically evident symptom. Memory impairment is often the first clinical symptom because 
the AD pathology first occurs in MTL structures; a region that is essential for memory (Squire 
and Zola-Morgan 1991). However, a slight decline in memory occurs frequently as a part of 
normal aging. Later on in AD, patients exhibit impairment in other cognitive domains, for 
example executive function. This stage is often called "preclinical" AD in the literature, but it 
is highly questionable whether this term should be used, because these patients clearly have 
symptoms of the disease, although their symptoms are not severe enough to fulfil the 
diagnostic criteria for AD. During this earliest stage of the disease, these deficits do not 
prevent patients from carrying out normal activities of daily living, and therefore these 
patients cannot be yet diagnosed as having dementia. In clinically overt AD, patients exhibit 
severe and progressive deficits in other cognitive domains. 
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2.1.3 Concept of mild cognitive impairment 
The belief that the cognitive symptoms of developing AD occur before the onset of clinical 
AD criteria fulfilling disease inspired researchers to try to find methods to discriminate these 
patients from healthy individuals. The starting point for most of the studies was memory 
impairment, because this is often considered as the first clinical sign of AD. However, 
memory impairment was not sufficient to be used alone, because it is associated with normal 
aging and other etiologies as well. Therefore more extensive criteria that aimed for more 
accurate distinction of AD patients were developed.(Table 1.) Several different criteria were 
introduced, but the fundamental tenet was that the patient would exhibit impairment beyond 
normal age related process but nonetheless would not be considered as being demented.  
 
 
Table 1. Clinical criteria proposed for diagnosis of cognitive impairment 
CIND Objective impairment in one or more cognitive domains  
No dementia 
AAMI Subjective memory impairment 
Objective memory impairment compared to normative values  
AACD Subjective memory impairment 
Objective memory impairment compared to age-adjusted normative values 
CDR 0.5 Subjective memory impairment 
CDR score 0.5 
Amnestic MCI Subjective memory impairment 
Normal activities of daily living 
Normal general cognitive functioning 
Objective memory impairment compared to age-adjusted normative values 
No dementia 
CIND, cognitive impairment, no dementia; AAMI, age-associated memory impairment; 
AACD, aging-associated cognitive decline; CDR, clinical dementia rating; MCI, mild 
cognitive impairment. 
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2.2 MILD COGNITIVE IMPAIRMENT AND EARLY DIAGNOSIS OF AD 
2.2.1 Mild cognitive impairment is a heterogeneous disorder 
Initially, the term MCI was considered as a transitional state between cognitively healthy and 
clinically diagnosable AD. Currently, this view has broadened to encompass a state in which a 
patient exhibits cognitive impairment that is measurable in some objective way but the patient 
is not demented. One of the most extensively used set of criteria is based on that proposed by 
Petersen and co-workers (Petersen et al. 2001). The criteria divide the clinical presentation of 
MCI into four categories; MCI amnestic, MCI amnestic multiple domains, MCI single non-
memory domain and MCI multiple non-memory domain categories. The criteria also 
acknowledge other possible causes of MCI than AD. Since AD is the most common 
dementing disease, it is also the most common etiology of MCI, either alone or as a 
concomitant pathology. AD is associated especially with amnestic MCI. It must be noted 
though that many patients with MCI do not have any underlying progressive disease. 
 
Another popular definition of MCI is simply using the CDR score of 0.5 as a clinical criterion 
for MCI (Morris et al. 2001). The main outcome of these patients is AD, but also vascular 
dementia (VaD) and dementia with Lewy bodies (DLB) pathologies may develop. In many 
studies, this criterion for MCI is divided into domain specific subgroup depending on what 
cognitive domain is affected, for example amnestic or executive subtype. The problem with 
this definition is that the group of patients with a CDR score of 0.5 include both patients with 
MCI and patients with very mild dementia.  
 
Cognitive impairment before the onset of clinically overt dementia is associated with other 
dementing diseases in addition to AD. The progression to other dementias was suggested to 
be associated with a decline in non-memory domains (Petersen et al. 2001). Indeed, a recent 
study reported that all of the MCI patients who progressed to FTD exhibited a decline in a 
single non-memory domain (Yaffe et al. 2006). Furthermore, another study reported that 
behavioural and affective symptoms together with executive dysfunction without decline in 
memory are associated with the development of FTD (de Mendonca et al. 2004). Vascular 
cognitive impairment (VCI) is proposed to be a prodromal condition of VaD (Bowler 2005). 
However, VCI patients include a very heterogeneous group of patients who progress to AD 
almost as often as to VaD and on the other hand, patients who fulfil the more general criteria 
for MCI often develop VaD frequently (Meyer et al. 2002b, Wentzel et al. 2001). A recent 
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study showed that both amnestic and non-amnestic MCI patients frequently develop dementia 
and also amnestic MCI patients developed VaD and DLB (Fischer et al. 2007). Furthermore, 
a neuropathological assessment of amnestic MCI patients who progressed to clinical dementia 
revealed that cognitive features cannot predict the development of AD associated 
neuropathology and most patients exhibit two or more different pathological features 
concomitantly (Jicha et al. 2006). 
 
No matter what definition is used at the present, those patients diagnosed as having MCI 
include also patients who have no progressive neurodegenerative disorder. Psychiatric 
disorders, especially depression, may cause a cognitive decline without any progression to 
dementia (Ganguli et al. 2006). Depression is also an important condition to consider in the 
differential diagnosis of AD. Furthermore, anticholinergic drugs could contribute to cognitive 
impairment to such an extent that the patient may be diagnosed as having MCI (Ancelin et al. 
2006). Therefore, it is not surprising that the group of patients diagnosed as having MCI will 
include some patients who eventually develop dementia, some who remain cognitively stable 
at MCI stage and even some who improve to become cognitively normal.  
 
2.2.2 Pathological findings 
The neuropathology of AD develops slowly during a long preclinical phase of the disease. 
Gradually the amount of neuropathology reaches a threshold to evoke cognitive symptoms 
that fulfil the clinical criteria for AD. Therefore it would be logical to presume that patients 
with MCI would display a substantial amount of AD associated neuropathology in their brain, 
though less than that found in patients with AD. Indeed, patients with MCI display marked 
AD neuropathology and its degree lies between the situation in cognitively healthy and AD 
patients with both CERAD and Braak staging (Bennett et al. 2005, Petersen et al. 2006). The 
NFT pathology of AD develops in a highly hierarchical sequential manner (Braak and Braak 
1991). Consistent with this model, MCI patients have elevated number of NFTs in MTL 
structures when compared to healthy controls (Guillozet et al. 2003, Markesbery et al. 2006). 
The number of NFTs in MTL correlates with memory function (Guillozet et al. 2003). 
Furthermore, the early AD patients have an elevated number of NFTs in MTL and other brain 
areas as well (Markesbery et al. 2006). The extent of amyloid pathology falls also between the 
healthy controls and AD patients (Bennett et al. 2005, Markesbery et al. 2006). However, the 
number of NFTs correlate better with dementia severity, the number of amyloid plaques do 
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not display such a clear correlation (Berg et al. 1998). Since AD associated neuropathology is 
so prominent in MCI patients, some investigators have proposed that MCI is in fact a 
preclinical or early phase of AD (Markesbery et al. 2006, Morris et al. 2001). The picture is 
not quite so straightforward since both plaques and tangles are consistently found in the brains 
of cognitively healthy subjects, (Price and Morris 1999) even to an extend that should they 
have been examined simply in histopathological terms, the individuals would have been 
described as exhibiting AD pathology (Neuropathology Group. Medical Research Council 
Cognitive Function and Aging Study 2001). 
 
2.2.3 Neuropsychological findings 
Since memory impairment is a key feature in the most widely used MCI criteria, it has also 
been the most extensively studied cognitive domain in MCI (Petersen et al. 2001). Many 
recently published, longitudinal studies have used the earlier criteria in which a memory 
complaint was required for MCI diagnosis and impairment in other domains was prohibited 
(Petersen et al. 1999). However, several other cognitive domains have been studied, for 
example executive function, attention, praxis and language and visuospatial skills. 
 
Although memory impairment is the most widely studied feature of MCI, isolated amnestic 
MCI is rare (Rasquin et al. 2005, Ribeiro et al. 2006, Ritchie et al. 2001, Tabert et al. 2006). 
In one study that included a consecutive sample of MCI patients, only 1.8% of the patients 
exhibited an isolated amnestic deficit. A total of 64.2% had multiple domains impaired and 
17.0% of the MCI patients had a single non-memory domain impairment (Nordlund et al. 
2005). In another study, 41.5% of the MCI patients in a memory clinic cohort did not have 
memory impairment (Rasquin et al. 2005). Even when relatively strict criteria for amnestic 
MCI are used, patients may also exhibit impairment in other cognitive domains if a detailed 
assessment of these other cognitive domains is performed (Kramer et al. 2006). 
 
Many MCI patients have impairment in executive functions on conjunction with memory 
impairment (Lopez et al. 2006, Tabert et al. 2006) but executive dysfunction occurs also in 
patients without memory impairment (Lopez et al. 2006). A slight executive dysfunction may 
appear before any disturbances in functions of activities of daily living (Ready et al. 2003). 
Impairment in executive functions and language skills in MCI patients may be even more 
common than memory impairment (Nordlund et al. 2005). These findings challenge the 
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hypothesis that an isolated memory deficit is the first symptom of developing dementia and 
the symptoms then extend to other cognitive domains only with disease progression (Ribeiro 
et al. 2006). 
 
2.2.4 Other features in mild cognitive impairment 
Neuropsychiatric symptoms are relatively common in MCI patients, as many as 59% of 
patients have at least one neuropsychiatric symptom and up to 36% have three or more 
symptoms (Feldman et al. 2004). The most common symptoms noted in that study were 
depression, irritability, anxiety, agitation and apathy and the appearance of neuropsychiatric 
symptoms was associated with more severe cognitive impairment (Feldman et al. 2004). 
Another study reported that MCI patients had increased agitation, dysphoria, anxiety, apathy 
and irritability when compared to healthy controls. AD patients had similar symptoms, only 
the extent of delusional behaviour was further increased in AD when compared to MCI 
patients (Hwang et al. 2004). On the contrary, a large population-based study found that even 
though MCI patients have an elevated number of neuropsychiatric symptoms when compared 
to healthy controls, the AD patients exhibit still significantly more symptoms than MCI 
patients (Lyketsos et al. 2002). Nonetheless, neuropsychiatric symptoms, especially mood 
disturbances are common in MCI patients and are detrimental to the well-being of both 
patients and their families. 
 
Although the decline in activities of daily living is restricted in the MCI criteria, a slight 
decline in functional capabilities is common in MCI patients (Farias et al. 2006). Those 
patients with a slight impairment in activities of daily living progress to dementia at a higher 
rate than patients with no functional decline and inclusion of decline in complex activities of 
daily living in MCI criteria might improve the sensitivity for development dementia (Peres et 
al. 2006). Motor dysfunction, particularly the parkinsonian signs, has also been associated 
with MCI and developing dementia (Aggarwal et al. 2006, Boyle et al. 2005). 
 
2.2.5 Epidemiology and prognosis 
Given the heterogeneity of the different criteria for MCI, it is not surprising that the incidence 
and prevalence rates of MCI in different studies vary greatly. The incidence, prevalence and 
progression rates to dementia are generally higher in clinic based studies than in population 
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based studies. When the cognitive impairment is defined according to broad criteria, the 
prevalence in the elderly population is high. The prevalence rate for age-associated cognitive 
decline (AACD) varies between 19.8% to 26.6% (Hanninen et al. 1996, Ritchie et al. 2001), 
but prevalence rates as low as 3.1% have been reported (Kumar et al. 2005). The prevalence 
of age-associated memory impairment (AAMI) has been reported to be 29% to 39% 
(Goldman and Morris 2001, Koivisto et al. 1995) or as low as 1.0% (Kumar et al. 2005). The 
prevalence of cognitive impairment no dementia (CIND) is close to the prevalence of AACD 
and AAMI, 16.8% (Graham et al. 1997). 
 
The prevalence for MCI, defined with the Petersen criteria (Petersen et al. 1999, Petersen et 
al. 2001) is generally lower but also varies in the different studies. One of the reasons for 
these varying results is that even though the Petersen criteria are used, there have been 
numerous small modifications to the criteria between the studies. The prevalence and 
incidence rates vary also between different populations. In the population-based studies the 
prevalence rates vary between 2.8% and up to 28.3% (Hanninen et al. 2002, Larrieu et al. 
2002, Lopez et al. 2003a, Manly et al. 2005). The prevalence of amnestic MCI is lower than 
the prevalence of MCI that also permits inclusion of other cognitive deficits. When both 
criteria for MCI were assessed in the same population, the prevalence for amnestic MCI was 
6% and for the multiple cognitive deficits MCI 16% (Lopez et al. 2003a). In a Canadian 
population, the prevalence for amnestic MCI was only 1.0% (Fisk et al. 2003). The 
combination of memory impairment with impairment in another cognitive domain seems to 
be the most prevalent MCI type (Lopez et al. 2006, Ribeiro et al. 2006). The reported 
incidence rates in turn are between 9.9/1 000 and 25.9/1 000 person years among the non-
demented elderly (Larrieu et al. 2002, Solfrizzi et al. 2004, Tervo et al. 2004). 
 
The prognosis of MCI is heterogeneous possibly due to differences in etiology, studied 
population and inclusion criteria. Although MCI is viewed as the transitional state between 
the healthy aging and clinically overt dementia, i.e. an indication of a dementing disease in 
progress, as many as 40% of MCI patients revert to normal (Larrieu et al. 2002). Some MCI 
patients remain stable and are still classified as MCI at the follow-up as well. The most 
prevalent dementing disease as the outcome of progressive MCI is AD. Clinic based studies 
usually report higher conversion rates than the population based studies. The clinic based 
studies generally report conversion rates of 10-15% per year (Bozoki et al. 2001, Petersen et 
al. 1999, Rasquin et al. 2005). Conversion rates in population based studies are usually about 
   29
2-10% (Fisk et al. 2003, Larrieu et al. 2002, Solfrizzi et al. 2004). The reasons for this might 
be that the clinic based studies include more selected samples and possibly patients with 
slightly more advanced disease (Arnaiz et al. 2004). In a clinic based study that included only 
patients who were referred to the clinic by primary care physician after at least a three month 
history of memory complaint, the conversion rate was a high as 41% after one year and 64% 
after two year follow-up (Geslani et al. 2005). Furthermore, population based studies may 
include patients with reversible causes for cognitive impairment, for example anticholinergic 
drug use (Ancelin et al. 2006). The type of cognitive impairment also affects conversion rate. 
In a clinic based study that included patients with isolated amnestic MCI symptoms, the 
yearly conversion rate was 21.4% which is higher than that found in most clinic based studies 
(Perri et al. 2007). It seems that those MCI patients who have underlying progressing disease 
tend to convert to dementia within a few years time because the yearly conversion rates 
decrease in longer follow up from 10.8% in the first year to a mere 2.5% in the fifth and 
following years (Visser et al. 2006). 
 
The risk factors for MCI are essentially similar to those for AD. The most important risk 
factor is increasing age. The strongest genetic risk factor for MCI and progression of MCI to 
dementia is the presence of at least one ApoE 4 allele (Hsiung et al. 2004, Manly et al. 2005, 
Petersen et al. 1995, Tervo et al. 2004). The ApoE 4 allele is especially detrimental to 
episodic memory, but it is also associated with accelerated decline also in other cognitive 
domains in the follow-up (Wilson et al. 2002). People with lower levels of formal education 
are at higher risk for MCI (Kivipelto et al. 2001, Lopez et al. 2003b, Manly et al. 2005, Tervo 
et al. 2004). Vascular risk factors, cardiovascular disease and elevated blood pressure, 
increase the risk of MCI and conversion to AD (Lopez et al. 2003b, Ravaglia et al. 2006, 
Solfrizzi et al. 2004, Tervo et al. 2004). An elevated blood cholesterol at midlife results in 
increased susceptibility for MCI later in life. Subjects with elevated blood pressure and high 
blood cholesterol at midlife are 2.7 times more likely to develop MCI two decades later than 
those subjects with normal values (Kivipelto et al. 2001). Cerebrovascular disease determined 
by MRI-identified infarcts also increases MCI risk (Lopez et al. 2003b). However, the 
association between the hypertension and MCI has not been found is other studies (Manly et 
al. 2005). Nonetheless, vascular risk factors seem to be associated with the development of 
MCI at least in some populations. Whether this association is causative is yet to be 
determined. The use of anticholinergic drugs may contribute to the cognitive impairment, 
such that after cessation of drug use the cognitive status returns to normal. 
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2.2.6 Towards a consensus - current concept of mild cognitive impairment 
The heterogeneity of MCI criteria, epidemiology, prognosis and clinical outcome has raised 
some inevitable questions. First, is the syndrome currently called MCI in reality a uniform 
clinical entity? The etiology has been shown to be caused by several different pathological 
conditions or be even iatrogenic. Secondly, if the concept of MCI is accurate enough to 
identify patients with incipient AD, should the AD diagnosis itself be modified so that it 
includes these currently so called preclinical AD patients? Many researchers already consider 
MCI as early AD. 
 
International Working Group on Mild Cognitive Impairment presented recommendations for 
general criteria for MCI after a symposium attended by specialists in different fields of 
dementia research (Winblad et al. 2004). Figure 1 represents the stepwise diagnostic process 
of MCI recommended by the group. The main difference with the former criteria is that there 
must be evidence of decline over time, the cognition of the patients is not compared to age 
adjusted normative values only. Also the MCI Working Group of the European Consortium 
on Alzheimer's Disease has recently proposed a new three stage diagnostic procedure for MCI 
(Portet et al. 2006). These criteria are essentially the same as those in the previous consensus 
report. In brief, to receive a MCI diagnosis, the patient needs to have a cognitive complaint, 
not necessarily a memory complaint, expressed by either the patient or a relative. There needs 
to be decline in cognitive functioning within the past year and the cognitive impairment 
should be corroborated by objective testing. Slight impairment in complex tasks of daily 
living are allowed but dementia must be excluded. The MCI subtype is then determined and 
additional examinations are initiated for detecting the underlying pathology. 
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Figure 1. The recommendations of diagnostic classification process for MCI patients from 
the International Working Group on Mild Cognitive Impairment. Adapted from Winblad et al. 
2004. 
 
 
2.3 DEVELOPMENT OF DIAGNOSTIC TOOLS FOR EARLY DIAGNOSIS OF 
ALZHEIMER'S DISEASE 
2.3.1 Search for a biomarker of early AD 
When the diagnosis of AD is possible using current methods, the disease process is already 
far advanced. Even the most sophisticated neuropsychological testing and clinical 
examination cannot reliably pinpoint those MCI patients who will eventually develop AD, 
much less those subjects who are still cognitively healthy but already have on-going 
neuropathology processes in the brain (Driscoll et al. 2006). Also, current methods are not 
sensitive enough to observe the possible, disease-modifying effects of different treatments for 
AD, either current or still experimental therapies. Therefore, there is a dire need for an 
   32
objective biomarker for AD. 
 
The Working group on "Molecular and Biochemical Markers of Alzheimer's Disease" stated 
in 1998 that a biomarker should be able to detect a fundamental feature of AD 
neuropathology, be validated in neuropathologically confirmed AD cases, and it should have 
sensitivity and specificity of >80%. It should also be precise, reliable, non-invasive, simple to 
perform and inexpensive (Consensus report of the Working Group on: "Molecular and 
Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research 
Institute of the Alzheimer's Association and the National Institute on Aging Working Group. 
1998). Since AD has a long preclinical stage of the disease, the biomarker should also be 
predictive. In AD, naturally, the biomarker should be relevantly linked to either amyloid- or 
tau pathology. 
  
There are two approaches for searching possible biomarkers. The discovery type of approach 
searches new biomarkers from plasma or CSF from a limited number of cases using methods 
that analyse many different molecules simultaneously, for example proteomics. When it is 
believed that there is a molecule that differs between the AD patients and controls, this 
molecule is identified and then examined further in larger study population. Another approach 
is the hypothesis driven search for a biomarker. Some already known feature of AD 
associated pathology is studied in a group of AD patients and healthy controls, and the 
accuracy of this feature in distinguishing patients with AD is calculated. For example atrophy 
of MTL structures is a well known characteristic of AD, and MRI imaging of atrophy has 
been assessed as a potential biomarker. 
 
The key requirement for an AD biomarker is that it should be validated in neuropathologically 
confirmed AD cases. Neuropathological confirmation could be reached either by biopsy of 
the brain, which is not in practice in AD diagnostics, or by neuropathological examination 
after death. Therefore the majority of the studies on biomarkers are conducted on clinical 
cohorts and this leads to some problems. The clinical diagnosis of AD reaches relatively high 
accuracy in experienced clinical units, but nonetheless, sensitivity remains at about 85% of 
the AD cases. Furthermore, the accuracy of clinical AD diagnosis is poor especially in the 
early stages of the disease, so the follow-up should be long enough to detect true AD patients. 
This problem is of course even more severe when studying MCI patients, who do not fulfil 
the criteria for even possible AD. Therefore, when studying AD biomarkers for prediction of 
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AD in MCI patients, the study population needs to be large and the follow-up has to last 
several years at the minimum. Another significant problem is that some cognitively healthy 
subjects exhibit substantial AD type neuropathology (Price and Morris 1999). On the other 
hand, some patients with severe cognitive impairment display very little neuropathology. It is 
also common that patients with other dementias, for example VaD or DLB, have concomitant 
AD neuropathology or AD patients have vascular or LB pathology (Neuropathology Group. 
Medical Research Council Cognitive Function and Aging Study 2001). The presence of 
different pathologies cannot be detected by the current clinical methods.  
 
2.3.2 Imaging 
At present in AD diagnosis, the brain imaging is used mainly for the exclusion of other 
possible causes of dementia, for example vascular disease. In MRI and CT it is also possible 
to see general brain atrophy in AD patients, but this atrophy is in no means either sensitive or 
specific to AD. Since imaging techniques are non-invasive, there has been great interest in 
developing imaging based methods on an early diagnosis of AD. 
 
2.3.2.1 Magnetic resonance imaging 
In addition to general brain atrophy, ongoing neurodegeneration of AD causes atrophy of 
MTL structures, especially HC and EC. The MTL atrophy occurs early in development of 
AD, which is in accordance with the Braak model of AD pathology (Braak and Braak 1991). 
This atrophy can be seen in CT, but MRI has proved to be better and more sensitive especially 
in detecting slight changes. Since the AD neuropathology begins from MTL, the HC and EC 
atrophy has been studied extensively in the hope of finding a possible preclinical imaging 
marker for AD. Several studies have shown that EC and HC atrophy is a typical feature of AD 
(Bobinski et al. 2000, Jack et al. 2002, Pennanen et al. 2004) and it is associated with 
decreased number of neurones of the region (Bobinski et al. 2000, Simic et al. 1997). 
However, MTL atrophy is not specific to AD but it also occurs in other neurodegenerative 
diseases (Jack et al. 2002). In MCI patients, the atrophy seems to lie between the healthy 
subjects and AD patients (Pennanen et al. 2004). Individual variability is large, but there is 
evidence that MTL atrophy may be useful in detecting those MCI patients who are at greater 
risk for development of AD. Since EC is affected before HC by AD pathology, especially 
during MCI stage of the disease, measurement of EC and HC separately may have better 
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diagnostic value than evaluating overall MTL atrophy (Pennanen et al. 2004). Nonetheless it 
is possible that because the EC is a rather small structure, the technical and anatomical 
limitations may nullify this theoretical benefit (Xu et al. 2000). 
 
A more practical clinical way of assessing MTL atrophy is to use a qualitative approach, 
because it enables grading of MTL atrophy from one imaging plane. The grading system can 
be easily learned, and acceptable inter-rater accuracy can be achieved (Scheltens et al. 1992). 
This type of rating can distinguish AD patients from healthy controls with an accuracy of 
96% when used in a clinically rational context (Wahlund et al. 2000). It can also be used as an 
aid to predict AD in MCI patients (Bouwman et al. 2006, Korf et al. 2004). Volumetric 
analysis is more detailed and may have better predictive accuracy. However, volumetric 
analysis is time consuming and laborious and it places great demands on the skills of the 
analyst. Moreover, HC and EC atrophy may not provide significant added value for a 
diagnosis between AD and other dementias when compared to neuropsychological testing. In 
a study comparing the diagnostic value of mini mental state examination (MMSE) and MTL 
atrophy, the overall accuracy of MMSE alone was 88% whereas MMSE in conjunction with 
volumetric or visual MTL atrophy rating was only 90% (Wahlund et al. 2000). Another study 
examined the predictive value of neuropsychiatric assessment and MTL atrophy for 
development of dementia and found that the accuracy of MMSE together with two other 
neuropsychiatric tests was 79.6% and accuracy of neuropsychiatric tests together with MTL 
atrophy 86.8% (Devanand et al. 2007). Therefore, at least for the time being, inclusion of 
volumetric MRI is not appropriate as a component of the clinical work-up. Functional MRI 
has also been assessed as a possible diagnostic aid for early AD, but the results are varying 
and the method is very laborious for both patient and analyst. 
 
2.3.2.2 Functional imaging 
Positron emission tomography (PET) and single photon emission computed tomography 
(SPECT) have been studied as possible biomarkers for AD. The most commonly used method 
in PET is the examination of regional glucose metabolism of different brain areas by using 
radio-labelled [18F] fluorodeoxyglucose. SPECT is used for imaging of regional blood flow. 
In neuropathologically confirmed patients, the hypoperfusion in parietal and temporal lobes 
yielded a sensitivity of 89% and a specificity of 80% against healthy controls and patients 
with other dementias (Jobst et al. 1998). Another study showed that the severity of 
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hypoperfusion was associated with the severity of cognitive impairment in AD patients 
(Waldemar et al. 1994). Temporal lobe hypoperfusion occurs already in patients with 
amnestic symptoms and hypoperfusion of posterior cingulate cortex has been reported to 
differentiate the MCI patients with a cognitive decline at the five year follow-up from stable 
MCI patients with 79% sensitivity and 67% specificity (Hogh et al. 2004, Johnson et al. 
2007). The accuracy of PET imaging seems to be better than the accuracy of SPECT 
(Mosconi 2005). The hypometabolism in MTL structures and posterior cingulate cortex has 
been shown to occur already in mild AD (Mosconi et al. 2007). Hypometabolism in parietal 
and temporal regions was claimed to differentiate AD patients from controls with 93% 
sensitivity and specificity and MCI patients who develop dementia from stable MCI patients 
with 93% sensitivity and 82% specificity (Anchisi et al. 2005, Herholz et al. 2002). 
 
2.3.2.3 Molecular imaging 
However, it is another PET based technique that has been raised the greatest hopes of 
improving AD diagnostics. Thioflavin compounds are traditionally used in histopathological 
examination of many tissues because they bind to the amyloids formed by different 
amyloidogenic proteins. In AD, the thioflavin compounds are routinely used for staining 
amyloid plaques that contain fibrillar Aβ. Pittsburgh Compound-B (PIB) is a thioflavin T 
derivative that can cross the blood brain barrier (BBB). In living AD and amnestic MCI 
patients, the PIB load as detected in PET is significantly higher than in healthy controls 
(Kemppainen et al. 2007, Klunk et al. 2004), and PIB binding correlates with the extent of 
brain atrophy (Archer et al. 2006). PIB binding also correlates with hypometabolism in 
temporal and parietal cortices of brain, although this association is lacking in frontal cortex 
(Edison et al. 2007). The distribution of PIB binding in brain is in accordance with the 
distribution of amyloid pathology found in autopsy studies on AD patients (Kemppainen et al. 
2006). Furthermore, in a recent study, all of the examined AD patients had PIB positive scans. 
However, that study also reported that four of 12 frontotemporal lobar degeneration patients 
and one out eight controls displayed positive PIB binding (Rabinovici et al. 2007). It is 
possible that these false positives were subjects with underlying amyloid pathology, because 
no neuropathological validation was available. One obstacle to using PIB as a AD biomarker 
is that even though PIB binding accurately confirms the presence of amyloid, it seems that it 
cannot distinguish between the amyloid in plaques and as cerebral amyloid angiopathy in 
blood vessels (Bacskai et al. 2007). No large follow-up studies are available, but it does seem 
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plausible that PIB could be used as an imaging biomarker for amyloid pathology in AD and 
even for progressive MCI. 
 
2.3.3 Laboratory tests for Alzheimer's disease 
2.3.3.1 Plasma Aβ peptide  
A biomarker that could be found in plasma would be ideal because a blood sample is easy to 
obtain and routinely used in clinical practice, minimally invasive and safe. The credibility of 
plasma biomarker is supported by the fact that the BBB damage is associated with AD 
pathology. Since APP and its metabolites, including Aβ peptide can be found in plasma, their 
feasibility for use in AD diagnosis has been studied. A large variety of other types of 
molecules have also been studied, but the results have been variable and at least for the time 
being, none of them have any validity in AD diagnosis (Irizarry 2004). 
 
APP, PS1 and PS2 mutation carriers as well as patients with DS who possess three copies of 
the APP gene were shown to have elevated plasma Aβ42 levels when compared to control 
subjects (Mehta et al. 1998, Scheuner et al. 1996). Also AD patients were reported to have 
increased Aβ42 levels when compared to healthy controls (Younkin et al. 2000). Furthermore, 
AD patients and those patients who developed AD during the follow-up had increased Aβ42 
levels when compared to controls (Mayeux et al. 2003). Another study reported elevated 
plasma Aβ40 but no difference in plasma Aβ42 levels between AD patients and controls 
(Mehta et al. 2000). In addition, in a third study, neither Aβ40 nor Aβ42 were different 
between AD patients and controls, but they correlated with age in each group (Fukumoto et 
al. 2003). The picture is as diverse in patients with MCI; Aβ42 levels have been shown to be 
increased in women with MCI when compared to controls or men with MCI (Assini et al. 
2004) but in another study there was no difference between groups (Fukumoto et al. 2003). 
Other amyloid related molecules studied as potential biomarker include Aβ directed 
autoantibodies found in plasma and the ratio of platelet derived APP isoforms (Di Luca et al. 
1998).  
 
2.3.3.2 Cerebrospinal fluid amyloid beta peptide 
CSF is in direct contact with brain and thus reflects brain associated biochemical events better 
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than any other biological fluid. Therefore CSF is a more likely source for finding a clinically 
usable biomarker than plasma. Aβ, tau and phospho-tau are linked to AD associated 
neuropathological changes, and they have been the most widely studied potential biomarkers 
for AD. Although most of the CSF is produced in the choroid plexus by capillary filtration, a 
substantial proportion is derived from extracellular fluid of brain parenchyma and about 20% 
of CSF proteins are synthesized in brain. Aβ peptide is secreted during physiological 
metabolism and it is a normal constituent of human CSF (Haass et al. 1992, Seubert et al. 
1992). The first studies on total CSF Aβ as a biomarker for AD gave disappointing results. 
Studies showed that CSF total Aβ levels were decreased (Pirttila et al. 1994), increased 
(Nakamura et al. 1994) or not changed at all in AD patients (Motter et al. 1995, van Gool et 
al. 1995). After the discovery of the two main types of Aβ peptides in CSF, Aβ40 and Aβ42, 
it was found that CSF Aβ42 levels were consistently lower in AD (Motter et al. 1995). 
Subsequently it was established that not only CSF Aβ42 was lower in AD, but it also could 
distinguish patients with AD from healthy controls with reasonable accuracy, even in patients 
with mild AD (Blennow and Hampel 2003). 
 
In MCI patients the results have been somewhat inconsistent. In a cross-sectional study, a 
small group of subjects with mild memory impairment exhibited low CSF Aβ42 levels 
(Hulstaert et al. 1999), whereas another study on a larger group of MCI patients reported 
significantly elevated Aβ42 levels in MCI patients when compared to healthy controls (Jensen 
et al. 1999). In a follow-up study on 19 MCI patients, the baseline levels of CSF Aβ42 were 
similar between the MCI group and the healthy control group, but when the MCI patients 
developed clinically overt AD, then the Aβ42 levels decreased (Maruyama et al. 2001).  
 
There is huge interest in differentiating those MCI patients who will develop dementia from 
those who remain stable or even improve to cognitively healthy. One study included 15 
cognitively healthy controls and 16 MCI patients who developed dementia within one year 
follow-up, and it was found that MCI patients had significantly lower CSF Aβ42 levels at the 
baseline (Andreasen et al. 1999). In another study, the baseline Aβ42 levels were lower in 
MCI patients who developed AD or had some other progressive cognitive impairment but did 
not develop dementia within an 18 month follow-up when compared to those MCI patients 
whose cognition remained stable (Riemenschneider et al. 2000). Furthermore, a study that 
included 52 MCI patients found that those 23 patients who developed probable AD during a 
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seven month follow-up had lower Aβ42 levels when compared to nonconverters (Hampel et 
al. 2004). However, in a study including 53 MCI patients, of whom 22 developed AD during 
an average 20 month follow-up, the baseline Aβ42 levels did not reveal any statistically 
significant difference between converters and non-converters (Zetterberg et al. 2003). 
 
In studies on MCI patients, the follow-up period should be much longer than used in these 
studies, because the development of dementia in MCI patients may take several years. In a 
study with too short a follow-up time, the stable MCI group is likely to include patients who 
would develop dementia during longer follow-up. The results of studies with longer follow-up 
are starting to emerge. A large study with 137 MCI patients reported that those MCI patients 
who progress to dementia within an average of five years follow-up had decreased CSF Aβ42 
levels at the baseline (Hansson et al. 2006). Therefore, the reduced Aβ levels seem to be 
evident even several years before the onset of dementia. Furthermore, CSF Aβ42 levels were 
shown to be lower in cognitively healthy subjects who developed dementia after three years 
follow-up (Skoog et al. 2003). The same group have extended their study and observed that 
decreased Aβ42 levels are associated with decreased MMSE score after eight years follow-up 
(Gustafson et al. 2006).  
 
CSF Aβ levels are thought to be associated with the amyloid pathology of the brain, but few 
studies have compared CSF Aβ levels and brain pathology. One study correlated post mortem 
ventricular CSF Aβ42 levels to the amount of brain amyloid pathology and found that more 
pronounced amyloid pathology was associated with lower Aβ42 levels in CSF (Strozyk et al. 
2003). Other studies have reported decreased CSF Aβ42 levels in neuropathologically 
confirmed AD patients, but did not report data on the quantitative amount of amyloid 
pathology (Clark et al. 2003, Engelborghs et al. 2007). The reasons for the decreased CSF 
Aβ42 levels in AD are not known yet, but it is possibly due decreased production resulting 
from cell death or abnormal clearance from brain to CSF as amyloid plaques sequester the Aβ 
peptides. 
 
2.3.3.3 Cerebrospinal fluid tau 
CSF tau has been consistently shown to be increased in AD when compared to healthy 
subjects relatively soon after the measurement of CSF tau became possible (Jensen et al. 
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1995, Vandermeeren et al. 1993, Vigo-Pelfrey et al. 1995). The association between AD and 
increased tau levels has been corroborated also in neuropathologically confirmed patients 
(Clark et al. 2003). These results have been replicated in several studies, and CSF tau was 
established as one of the most promising biomarkers for AD (Blennow and Hampel 2003). 
CSF tau levels were found to be increased even in patients with very mild AD (Kurz et al. 
1998, Riemenschneider et al. 1996). In the cross-sectional setting, the patients with minimal 
memory impairment or MCI had higher CSF tau levels than the healthy controls (Hulstaert et 
al. 1999, Maruyama et al. 2001). Baseline tau levels were also associated with developing 
dementia in the follow-up (Andreasen et al. 1999, Maruyama et al. 2001, Riemenschneider et 
al. 2000, Zetterberg et al. 2003). There is evidence that in MCI patients, the CSF tau levels are 
increased in those patients who develop AD compared to those who develop some other form 
of dementia (Zetterberg et al. 2003). However, the association between increased tau and 
developing AD has not been confirmed in all studies (Buerger et al. 2002a). 
 
Although there is a body of evidence that increased CSF tau levels are associated with AD, 
even during an early stage of the disease, problems in using tau as a biomarker soon emerged. 
An increased tau level was not specific to AD, but seemed to be associated with many 
neurodegenerative states. In a population based study, the patients with VaD or mixed AD 
and VaD had similar tau values to AD patients (Andreasen et al. 1998). Increased tau levels 
were also reported from patients suffering from DLB or FTD (Arai et al. 1997). Extremely 
high tau values are found in patients with Creutzfeldt-Jakob disease (CJD) (Otto et al. 1997) 
and patients with recent stroke (Hesse et al. 2001). Although some of these findings proved 
inconsistent, it became obvious that tau mirrors neuronal and axonal damage in general rather 
than the neurodegenerative process of AD specifically. Thereafter, the search for a reliable 
biomarker moved on to find a more AD specific form of tau. 
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Table 2. The characteristics of CSF Aβ42 and tau in predicting dementia in MCI patients 
  Stable  
MCI 
Specificity 
Progressive 
MCI 
Sensitivity 
Overall 
Accuracy 
Positive LR 
 
Negative LR 
 
Riemenschneider et al. 
20021 
Aβ42 + tau 90% 
9 / 10 
90% 
9 / 10 
90% 
18 / 20 
9.00 (1.35-58.44) 0.11 (0.02-0.71) 
Hampel et al. 20042 Aβ42 
 
Tau 
57% 
13 / 23 
48% 
11 / 23 
83% 
 24 / 29 
90% 
26 / 29 
71% 
37 / 52 
71% 
37 / 52 
1.90 (1.61-3.12) 
 
1.72 (1.14-2.59) 
0.31 (0.13-0.73) 
 
0.22 (0.07-0.69) 
Maruyama et al. 20043 Tau 87.5% 
14 / 16 
88% 
36 / 41 
88% 
50 / 57 
7.02 (1.91-25.81) 0.14 (0.06-0.32) 
Hansson et al. 20064 Aβ42 + tau 82% 
46 / 56 
95% 
54 / 57 
88% 
100 / 113 
5.31 (3.01-9.34) 0.06 (0.02-0.19) 
The table contains all the studies that have provided sufficient information concerning stable 
and progressive MCI patients to make it possible to calculate diagnostic accuracy figures. 
Data presented as percentage and number of correctly allocated subjects in the group or as 
LR (95% CI). MCI, mild cognitive impairment; LR, likelihood ratio. 
1. Endpoint Alzheimer's disease, cut-off: Aβ42 = 240 + 1.18 ×  tau 
2. Endpoint Alzheimer's disease, cut-off: Aβ42 679 pg/ml and tau 479 pg/ml 
3. Endpoint dementia, cut-off: tau 320 pg/ml 
4. Endpoint Alzheimer's disease, cut-off: Aβ42530 pg/ml and tau 350 pg/ml 
 
 
2.3.3.4 Cerebrospinal fluid phospho-tau 
Phosphorylation of tau is a normal physiological event, and it may occur in several dozens of 
amino acid residues of tau. In AD, as well as in some other neurodegenerative diseases 
associated with tau pathology, tau is phosphorylated beyond the normal functional level. The 
result is hyperphosphorylated tau which impairs axonal transport and forms intracellular 
aggregates (Avila 2006). There are several assays for measurement of CSF phospho-tau, but 
the most widely utilized are the assays for phosphorylated at threonine 181 (phospho-tau181) 
and threonine 231 (phospho-tau231) both of which seem to perform equally well in 
discriminating AD patients from controls and patients with other neurological diseases 
(Hampel et al. 2004). 
 
Measurement of phospho-tau instead of total tau especially improves the discrimination of 
AD patients from patients with DLB or FTD (Hampel et al. 2004, Sjogren et al. 2001). The 
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benefits of phospho-tau are also that unlike total tau, phospho-tau is not markedly increased in 
CJD (Buerger et al. 2006b, Riemenschneider et al. 2003) or after a stroke (Hesse et al. 2001). 
Elevated phospho-tau levels have been found in progressive MCI patients (Arai et al. 2000) 
and phospho-tau levels have been reported to display a correlation to annual points lost in 
MMSE (Buerger et al. 2002a, Buerger et al. 2002b). 
 
2.3.3.5 Other possible CSF biomarkers 
Numerous different proteins that are present in CSF have been studied as potential biomarkers 
for AD in the past decade. Many of the studied proteins are related to different aspects of AD 
pathology, for example the presence of glycosylated acetylcholinesterase may reflect the 
changes of cholinergic system in AD brain (Saez-Valero et al. 2000). Apart from tau proteins, 
other molecules that accompany neuronal cell death have been examined; one example of 
these is tissue transglutaminase (Bonelli et al. 2002). There are also studies into a large 
number of possible biomarkers for inflammation of AD brain (Jia et al. 2005). Molecules that 
reflect homeostasis of the brain have been proposed as representing possible biomarkers, 
these include 24S-hydroxycholesterol which is a brain specific metabolite of cholesterol 
(Leoni et al. 2006) and isoprostane which is a marker for oxidative damage (Montine et al. 
2001). It is also possible that the most accurate diagnosis of early AD can be achieved by 
using a panel of several different biomarkers (Simonsen et al. 2007). Even though the above 
mentioned and numerous other molecules including neurofilament proteins, neuromodulin 
and neuronal thread protein have been studied (Blennow 2004), at the present, the only usable 
biomarkers are the CSF Aβ42, tau and phospho-tau levels in CSF.  
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3. AIMS OF THE STUDY 
 
AD is a disease that has been suggested to develop slowly over a time range of two decades 
before the first symptoms make their appearance. Neuropathology starts to develop early 
during a presymptomatic period of the disease, and at the first symptomatic stage, the 
pathology is already advanced. This is a great obstacle in treating the disease because 
repairing the already existing damage is currently impossible. Previous studies have suggested 
that changes in CSF biomarkers Aβ42, tau and phospho-tau can be used as a diagnostic aid 
especially in clinically challenging conditions, for example in the differentiation between mild 
AD and depression.  
 
At the onset of this study, little was known about these markers before the onset of clinical 
AD. Since AD neuropathology starts to develop decades before the appearance of symptoms, 
the original hypothesis was that AD associated changes in CSF biomarkers could be detected 
before these clinical signs of AD. The main aim of the study was to examine whether these 
changes would predict the development of AD in patients with MCI and whether there was an 
association between AD associated pathological changes in brain and the CSF biomarker 
levels. 
 
The specific aims of the study were: 
 
1. To study whether the CSF Aβ levels are related to amyloid pathology in the brain of the 
transgenic mouse model of AD. 
2. To study whether the AD associated changes in CSF biomarker are detectable before the 
clinical diagnosis of AD. 
3. To study whether these changes are predictive for AD when used as a diagnostic test. 
4. To study the association between the CSF biomarkers and changes in medial temporal 
lobe structures. 
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4. MATERIALS AND METHODS 
 
4.1 SUBJECTS 
4.1.1 Study population 
The study population was derived from two different sources. The majority, 107 of the 
subjects, were recruited from the neurological department of the Kuopio University Hospital 
to which they had been referred by their primary care physician due to neurological 
symptoms. The reasons for referral included headaches, dizziness and cognitive symptoms. 
Those patients who agreed to undergo lumbar puncture for research purposes were included 
in the study. The patients who were found to be neurologically intact or whose symptoms 
were caused by depression were designated as controls. The diagnosis of depression was 
based on the clinical examination and patients with depression were further referred to 
psychiatrist. The MCI patients included both amnestic MCI patients and patients with some 
other type of cognitive decline, for example executive dysfunction or impaired visuospatial or 
language skills. One subject with fibromyalgic pains, who entered the study as a control 
subject, was excluded due to receiving a diagnosis of AD ten years later. A total of 33 
subjects included in the study were part of a large population-based follow-up study of 
cognitive impairment in the elderly population of Kuopio region. Those patients who agreed 
to undergo lumbar puncture for research purposes were included in the study. All subjects 
gave informed consent and the study was approved at the Kuopio University Hospital Ethical 
Committee. 
 
In study II all of the MCI patients were analysed as a single group without any more detailed 
division into diagnostic groups. For study III, the MCI patients were divided into three 
different groups based on the MCI type: amnestic MCI (with or without any other cognitive 
impairment), executive MCI (with or without any other cognitive impairment, no amnestic 
symptoms) and other MCI (subjects with impairment in one or more cognitive domains other 
than memory or executive function). In study III, the control group was divided into patients 
with depression and other controls, since depression is one of the most important diseases to 
consider in the differential diagnosis of early AD. The study IV included all the MCI patients 
from the larger neuroimaging study (Pennanen et al. 2004) who had also agreed to a lumbar 
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puncture and therefore for whom biomarker data were available. All of these patients except 
one were also included in study III. In all of the studies II-IV, the MCI patients were further 
divided into those who remained cognitively stable and those who developed dementia during 
the follow-up.  
 
Baseline examination of all subjects included a neurological and neuropsychological 
examination, imaging of the brain (mainly computed tomography), and laboratory tests for 
exclusion of the secondary causes of cognitive decline according to Finnish guidelines. The 
subjects from whom the follow-up information was available formed the final cohort of the 
study. The follow-up examinations were performed yearly for the population based group. 
The patients from the clinic group were either seen again at the clinic or the follow-up data 
were later derived from the medical charts of the patients.  
 
4.1.2 Neuropsychological testing 
The large variety of neuropsychological tests was used to assess impairment in different 
cognitive domains. In the clinical group, the tests that were used varied because the baseline 
examination of patients was conducted over a period of several years. However, all of the 
domains that were studied in the population based group were assessed also in the clinical 
group. 
 
In the population based group, the following tests were used: Memory: Visual Reproduction 
Test (VR, immediate and delayed recall) from Wechsler Memory Scale (WMS) (Russel 
1975), Logical Memory Test (LM, immediate and delayed recall) from Wechsler Memory 
Scale-Revised (WMS-R) (Wechsler 1987), Word List Recall (immediate and delayed recall) 
from the CERAD Neuropsychological Assessment Battery (Morris et al. 1989), Delayed 
Recall of the Constructional Praxis from CERAD (Morris et al. 1989); Language: 
Abbreviated (15 items) Boston Naming Test (Kaplan et al. 1991), vocabulary subtest from the 
Wechsler Adult Intelligence Scale-Revised (WAIS-R) (Wechsler 1981); Attention and 
executive function: Verbal Fluency Test (Borkowski et al. 1967, Butters et al. 1987), Trail 
Making Test (Reitan 1958) parts A and B; Visuospatial skills: Constructional Praxis from 
CERAD (Morris et al. 1989), Block Design from the WAIS-R (Wechsler 1981); Global 
functioning: Mini-Mental State Examination (Folstein et al. 1975) (MMSE), Clock Drawing 
Test. (Morris et al. 1989) Subjects performing below the age-adjusted norms in at least one 
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cognitive domain were diagnosed as having MCI if they also had a score of 0.5 on the CDR 
scale (Morris 1993). The assessment of CDR score was based on a non-structured clinical 
interview on patient and caregiver. 
 
4.1.3 Diagnosis of dementia 
The diagnosis of dementia was based on the criteria of the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric Association 1994) and 
AD was diagnosed using the National Institute of Neurological and Communicative Disorders 
and Stroke and Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) 
criteria (McKhann et al. 1984). The diagnosis was made by consensus decision by two 
neurologists and two neuropsychologists. The diagnosis was made based on the clinical 
symptoms and neuropsychological test results. The diagnostic workup included the standard 
laboratory testing and imaging, mainly computed tomography, to exclude any other possible 
causes for dementia than AD. The diagnosis of dementia was done independently and blinded 
to the CSF biomarker data and the ApoE genotype.  
 
4.2 TRANSGENIC MICE 
4.2.1 Transgenic mice 
Two different doubly transgenic mouse lines were used in the study. Both lines carry an 
APP695 gene that includes the human Aβ domain with mutations K595N and M596L that are 
linked to Swedish familial AD pedigrees (APPswe). The first mouse line also carries a human 
PS1 gene with AD linked mutation A246E (APPswe/PS1 mice) (Borchelt et al. 1997). The 
second line carries a PS1-dE9 mutation (APPswe/PS1dE9) (Jankowsky et al. 2004). 
 
4.2.2 Surgical procedures 
The sampling method for mouse CSF was adapted from a previously described method 
(Meyding-Lamade et al. 1996). CSF was taken from 22 APPswe/PS1 mice at the age of 5 and 
7 months and from 39 mice at the age of 8, 10 and 13 months. From 36 APPswe/PS1dE9 
mice, the CSF sample was taken at the age of 6 and 9 months. CSF was collected by 
penetrating the dura in the cisterna magna with a 6-cm-long glass capillary that had a tip with 
an outer diameter of 0.5 mm. The sample was immediately transferred to a polypropylene 
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tube and stored at -70°C until analyses. The average collected volume of CSF was 
approximately 7 µl. 
 
After the last round of CSF sampling, the mice were transcardially perfused with 50 ml 
heparinized ice-cold 0.9% saline (10 ml/min), and the brains were rapidly removed. One 
hemibrain was immediately immersed in 4% paraformaldehyde in 0.1 M Na-phosphate buffer 
for 4 h and then transferred overnight to 30% sucrose solution. These samples were then 
stored in a cryoprotectant at -20°C until histological analyses. The other hemibrain was 
dissected on ice into selected brain areas (including HC and cerebellum) that were stored at -
70°C until ELISA analyses. 
 
4.2.3 Sample preparation for ELISA 
The analysis focused on the HC which was evaluated from all mice that were included in the 
study. The cerebellar Aβ42 was also studied from a subset of mice because the cisterna 
magna lies next to the cerebellum, and therefore it is possible that CSF Aβ42 originates from 
cerebellum instead of the main plaque forming areas of the brain, including HC. The tissue 
sample was first homogenized in phosphate buffered saline, pH 7.2, which contained a 
mixture of protease inhibitors (CompleteTM, Boehringen Mannheim, Germany). Tissue 
homogenates were then centrifuged at 218 000 × g for 2 h at +4°C. The supernatants that 
contained the soluble Aβ42 were collected and stored at -70°C until analyses. The remaining 
pellet containing the insoluble Aβ42 was further homogenized in guanidine buffer (5.0 M 
guanidine-HCl in 50 mM Tris-HCl, pH 8.0), incubated at room temperature for 3 h, 
centrifuged, and diluted to reduce the guanidine concentration to 0.5 M. 
 
4.2.4 Histology 
The brain was cut into 30 µm coronal sections, which were stained with W02 antibody 
(ZMBH, Heidelberg, Germany) that recognizes the human Aβ as described earlier (van Groen 
et al. 2003). Three stained sections through the HC were digitized using a Nikon Coolpix 990 
camera, and the images were converted to grey scale using the Photoshop 5 program. The 
percentage of area covered by the reaction product to Aβ (i.e. Aβ load) was measured using 
the ScionImage (NIH) program. 
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4.3 CSF BIOMARKER ANALYSES 
4.3.1 Aβ42 
Human CSF Aβ42 levels were measured by using an ELISA kit (Innogenetics, Ghent, 
Belgium). All analyses were done in duplicate. The mouse CSF Aβ42 levels were measured 
by using the High Sensitivity method provided in the same kit. Due to the small amount of 
available sample, the analyses were done without duplicates. The brain Aβ42 was measured 
by the High Sensitivity method according to the protocol, except that 0.5 M guanidine was 
added to the kit's standards when measuring the insoluble Aβ42 from brain tissue samples. 
This was done because guanidine significantly decreases the strength of the signal in ELISA 
and if the guanidine was missing from standards the results would have been erroneously low. 
The brain Aβ42 from the 7 month old mice was measured by using a Signal Select β-amyloid 
ELISA kit (BioSource International Inc.). 
 
4.3.2 Tau and phospho-tau 
CSF tau levels were measured by using an ELISA kit (Innogenetics, Ghent, Belgium). The 
CSF phospho-tau levels were measured by using an ELISA kit that measures specifically the 
Tau phosphorylated at residue 181. All analyses were made in duplicate. 
 
4.4 APOE GENOTYPING  
The ApoE genotype was determined by using a PCR based method (Tsukamoto et al. 1993). 
For the statistical analyses, the subjects were classified according their ApoE genotype; either 
by the presence (ApoE 4 positive) or absence (ApoE 4 negative) of ApoE 4 or the number of 
possessed ApoE 4 alleles (none, one or two ApoE 4 alleles). 
 
4.5 MAGNETIC RESONANCE IMAGING 
All subjects in study IV underwent a high resolution MRI in the Kuopio University Hospital. 
The images were acquired using a 1.5 Tesla Vision (Siemens, Erlangen, Germany), with a 3D 
magnetization prepared rapid acquisition gradient echo sequence (for the patients scanned in 
1998/1999, the parameters were: TR (time of repetition) = 9.7 ms, TE ( time of echo) = 4 ms, 
matrix 256×256, 1 acquisition and in plane resolution = 0.98 mm, while for the patients 
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scanned in 1999-2001 the parameters were: TR = 13.5, TE = 7, matrix 256x256, 1 acquisition 
and in plane resolution = 0.94 mm). Standard neuroanatomical landmarks were used to 
correct for possible deviations in any of the orthogonal planes and the scans were 
reconstructed into 2.0 mm thick contiguous coronal slices, oriented perpendicular to the 
intercommissural line. The hippocampi and EC were manually traced by a single tracer 
(C.P.), using custom-made software for a standard Siemens work console (Pennanen et al. 
2004). The boundaries of the regions of interest were outlined using a trackball driven cursor, 
always proceeding in an anterior to posterior direction. The coronal intracranial area at the 
level of the anterior commissure was measured and used for the normalization of the 
volumetric data according to the formula: (volume/intracranial area) x 100. The intraclass 
correlation coefficients for intrarater reliability were 0.96 for the HC and 0.95 for the EC 
measured from 10 subjects. All analyses were done blinded to the clinical data (Pennanen et 
al. 2004). 
 
4.6 STATISTICAL ANALYSIS 
All statistical analyses were performed by using SPSS software for Windows (SPSS Inc. 
Chicago, IL). The comparisons between the different groups of subjects were done by 
ANOVA with appropriate post hoc corrections. When the assumptions for normality were not 
met, the nonparametric tests were used. For the categorical data, the comparisons between 
different groups were made with Chi-square tests. The correlations between different 
variables were calculated by Pearson's correlation test or by Spearman's correlation test. The 
best cut-off values for development of dementia of different measures were determined by 
receiver operator characteristics (ROC) analysis. The odds ratios for different factors that 
might contribute to the conversion of MCI to dementia were determined by logistic regression 
analysis, so that only the patients with MCI at the baseline were included. Cox regression 
analysis was used for survival analyses.  
 
4.7 ETHICAL CONSIDERATIONS 
Elderly patients with cognitive impairment are a very special group to consider in clinical 
studies. Additional caution needs to be used when informed consent is obtained. All of the 
patients who entered the study were only slightly impaired at the time of inclusion into the 
study and thus capable of providing informed consent. Since CSF biomarkers and ApoE allele 
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analysis are not currently used in routine diagnostics, the results of these analyses were not 
revealed to the patients. 
 
Lumbar puncture is an invasive method that may be uncomfortable for the patient and 
sometimes has side effects. However, in a study on 342 subjects, it was shown to be a safe 
procedure, and even the post puncture headache, the most frequent side effect, was rare 
especially in the patients with AD and MCI (Peskind et al. 2005). On the other hand, the dire 
need for the development of methods for earlier diagnosis of AD is increasing as the 
treatment possibilities progress. Since CSF is in direct contact with brain, it offers the best 
potential as a reliable source of biomarkers to be used in future diagnostic aids. 
 
All of the animal experiments were conducted according to the Council of Europe and Finnish 
guidelines and approved by the State Provincial Office of Eastern Finland. 
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5. RESULTS 
 
5.1 ASSOCIATION BETWEEN CSF Aβ42 AND NEUROPATHOLOGY IN MICE 
The CSF Aβ42 levels increased significantly in APPswe/PS1 mice from age 5 months to 7 
months (p<0.001). None of the mice showed any amyloid deposits in the histology at this 
stage. Between the age of 8 to 13 months, the CSF Aβ42 levels remained stable, and at the 
age of 13 months a few amyloid deposits could be detected in all mice. The APPswe/PS1dE9 
mice had a few amyloid deposits already at the age of 6 months, but a severe amyloid 
pathology was observed only from the 9 months old mice. The CSF Aβ42 levels of 6 months 
old APPswe/PS1dE9 mice was comparable to the 13 months old APPswe/PS1 mice. The CSF 
Aβ42 levels decreased significantly during this time that the amyloid pathology advanced 
rapidly and the levels in 9 months old mice were significantly lower than the levels in 6 
months old mice (p<0.001). Taken together, the CSF Aβ levels increased before the 
development of amyloid pathology and reached a plateau where the levels remained until the 
levels decreased when full blown amyloid pathology developed. 
 
The CSF Aβ42 levels of 5 months old APPswe/PS1 mice correlated with the HC insoluble 
Aβ42 at the age of 7 months (r=0.48, p=0.03). Also the CSF Aβ42 levels of the 8 months old 
mice correlated with the HC insoluble Aβ42 of the 13 months old mice (r=0.53. p<0.001). 
The CSF levels that were measured from mice at the 13 months when the tissue sample was 
obtained showed weaker correlation (r=0.33, p=0.04). In the APPswe/PS1dE9 mice there was 
no correlation between the HC insoluble Aβ42 levels and the CSF Aβ42 levels at either time 
point.  
 
5.2 CLINICAL CHARACTERISTICS OF HUMAN SUBJECTS 
A total of 60 controls and 79 patients with MCI of whom 33 progressed to dementia were 
included in the study. Study II included 46 control subjects and 78 MCI patients. During the 
follow-up, 23 MCI patients developed AD. The age and gender distribution were similar in all 
groups. Study III included all of the patients from study II, except one control subject who 
was suffering from fibromyalgic pains and was cognitively healthy at the baseline but 
progressed to AD by the time of the last follow-up of study III. Study III included also one 
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additional MCI patient and the follow-up period was extended for many of the subjects. At 
the end of study III, the control group included 19 subjects with depression and 41 subjects 
with other neurological symptoms at the baseline. The MCI group consisted of 46 stable MCI 
patients and 33 who progressed to dementia. The age and gender distribution was similar 
between the groups. The follow-up period for the progressive patients ended at the time of 
diagnosis of dementia, and therefore the follow-up was shorter in the progressive MCI group. 
The presence of the ApoE 4 allele was more frequent in progressive MCI group than in the 
control or stable MCI groups. Table 3 presents the baseline demographic details of subjects in 
the different groups. 
 
At the baseline of study III, the MCI patients were divided into three groups according to the 
type of the cognitive impairment. The largest group was the amnestic MCI patients with a 
total of 47 patients. Eight had isolated amnestic MCI, 39 had impairment in some other 
cognitive domain as well. Seventeen patients had executive MCI and 15 patients had 
impairment in some other cognitive domain, for example language or visuospatial skills. In 
all, 51% of the amnestic MCI patients, 41% of the executive MCI patients and 13% of the 
other MCI patients progressed to dementia during the follow-up. Twelve of the stable MCI 
patients had cognitive impairment due to vascular reasons, the etiology of 32 stable MCI 
patients causing the cognitive impairment remained undetermined. The most frequent 
diagnosis in the progressive MCI group was AD, but the progressive MCI group included also 
five patients with dementia of mixed etiology and one VaD patient.  
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Table 3. The clinical characteristics of studied controls (n=60) and MCI patients (n= 79) at the baseline.  
 
 
 
Controls 
 
Stable MCI 
 
Progressive MCI 
 All OND Depression All Amnestic Executive Other All  Amnestic  Executive Other  
n 60 41 19 46 23 10 13 33 24 7 2 
Age 68.3±8.1 69.4±6.8 66.0±10.2 69.5±8.1 70.0±7.7 68.4±7.3 69.2±9.9 71.7±6.7 71.1±7.1 74.3±5.8 69.0±4.2 
Sex, 
men/women 
25 / 36 
42%/58% 
17 / 24 
41%/59% 
8 / 11 
42%/58% 
20 / 26 
44%/56% 
11 / 12 
48%/52% 
7 / 3 
70%/30% 
2 / 11 
15%/85% 
13 / 20  
39%/61% 
10 / 14 
42%/58% 
2 / 5 
29%/71% 
1 / 1 
50%/50% 
MMSE 
 
26.2±2.9 
missing 9 
26.7±2.5 
missing 6 
25.1±3.4 
missing 3 
24.1±2.5 23.3±3.1 24.3±1.8 24.2±1.7 23.9±2.7 23.8±2.9 23.9±1.9 25.5±3.5 
Follow-up, 
years 
3.94±2.22 3.85±2.13 4.13±2.45 4.57±3.09 3.87±2.63 5.90±4.23 4.77±2.71 3.52±1.95 3.50±2.09 3.00±1.41 5.50±0.71 
ApoE4 +/- 
 
21 / 39 
35%/65% 
13 / 28 
32%/68% 
8 / 11 
42%/58% 
15 / 30 
33%/67% 
missing 1 
7 / 15 
32%/68% 
missing 1 
3 / 7 
30%/70% 
5 / 8 
38%/62% 
26 / 7 
79%/21% 
20 / 4 
83%/17% 
4 / 3 
57%/43% 
2 / 0 
100%/0% 
Etiology    12 VCI 
2 FD 
32 NAS 
6 VCI 
1 FD 
16 NAS 
4 VCI 
 
6 NAS 
2 VCI 
1 FD 
10 NAS 
27 AD 
5 Mixed 
dementia 
1 VaD 
21 AD 
3 Mixed 
dementia 
5 AD 
2 Mixed 
dementia 
1 AD, 
atypical 
1 VaD 
Data presented as mean ± SD or number of subjects and percentage of all subjects in the group. MCI, mild cognitive impairment; OND, other 
neurological diseases; VCI, vascular cognitive impairment; FD, suspected frontal degeneration; NAS, non aliter specificatus; AD, Alzheimer's 
disease; VaD, vascular dementia. 
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5.3 CEREBROSPINAL FLUID BIOMARKER LEVELS AT BASELINE 
In studies II and III, the CSF Aβ42, tau and phospho-tau levels were not statistically different 
between the controls and stable MCI patients. However, in progressive MCI patients, the CSF 
Aβ42 levels did decrease and tau and phospho-tau levels increased when compared either 
controls or stable MCI patients.  
 
The CSF biomarker levels were not different between men and women. In study III, tau 
levels correlated with age in the control group (r=0.290, p=0.025), but none of the measured 
biomarkers correlated with age in the whole study group or any other diagnostic group. 
However, the ApoE genotype was found to have an effect on all of the studied biomarkers in 
the control group and on Aβ42 in the progressive MCI group.(Figure 2) 
 
 
 
Figure 2. CSF levels of Aβ42 and tau in different diagnostic groups. White bars: subjects 
with no ApoE 4 alleles (n=76), grey bars: subjects with one ApoE 4 allele (n=44) and black 
bars: subjects with two ApoE 4 alleles (n=18). 
 
 
 
5.4 CUT-OFF VALUES OF DIFFERENT BIOMARKERS FOR DEVELOPING AD 
The cut-off values for different biomarkers were determined by using a ROC analysis. The 
analysis included all controls subjects and progressive MCI subjects from study II. Figure 3 
shows an example of the result of Aβ42 ROC analysis in a visual form. 
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Figure 3. The ROC results for Aβ42. The analysis included 46 controls and 23 MCI patients 
who developed AD during the study. 
 
 
 
The best cut-off value was the point on the curve that had the highest sensitivity and 
specificity, in the case of Aβ42 the value was 452 pg/ml, area under curve (AUC) 0.831 
(0.726-0.935). The cut-off value for tau was 399 pg/ml, AUC 0.869 (0.786-0.951) and 
phospho-tau 70 pg/ml, AUC 0.839 (0.744-0.935). The test for Aβ42 was positive if the CSF 
Aβ42 level was below the cut-off value and for tau and phospho-tau if the CSF levels were 
above the cut-off value. These cut-off values were used to determine the sensitivity and 
specificity of these biomarkers for progressive MCI.(Table 4) Also the 5 mixed dementia 
subjects and the one VaD patient were included in the analysis. 
 
5.5 PREDICTORS OF DEVELOPING DEMENTIA 
The predictive value of different clinical measures was determined by logistic regression 
analysis on study III. The analysis included only MCI patients. The patients' age, sex or 
MMSE score at the baseline were not significant predictors for dementia. The patients 
carrying the ApoE 4 allele were about 7 times more likely to develop dementia during the 
study. The patients with two ApoE 4 alleles were also younger at the time of dementia 
diagnosis. 
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Table 4. The characteristics of different measures as a diagnostic test for developing 
dementia. 
 Controls 
Specificity 
Stable 
MCI 
Specificity 
Progressive 
MCI 
Sensitivity 
Overall 
Accuracy 
Positive LR 
Controls 
Stable MCI 
Negative LR 
Controls 
Stable MCI 
Aβ42 90.0% 
54 / 60 
80.4% 
37 / 46 
57.6% 
19 / 33 
79.1% 
110 / 139 
5.76 (2.55 - 12.99) 
2.94 (1.53 - 5.67) 
0.47 (0.31 - 0.71) 
0.53 (0.35 - 0.81) 
Tau 76.7% 
46 / 60 
63.0% 
29 / 46 
84.8% 
28 / 33 
74.1% 
103 / 139 
3.64 (2.25 - 5.88) 
2.30 (1.53 - 3.44) 
0.20 (0.09 - 0.45) 
0.24 (0.10 - 0.56) 
Phospho-tau 66.7% 
40 / 60 
60.9% 
28 / 46 
84.8% 
28 / 33 
69.1% 
96 / 139 
2.55 (1.73 - 3.74) 
2.17 (1.47 - 3.20) 
0.23 (0.10 - 0.52) 
0.25 (0.11 - 0.58) 
Aβ42 + tau 93.3% 
56 / 60 
89.1% 
41 / 46 
48.5% 
17 / 33 
82.0% 
114 / 139 
7.73 (2.83 - 21.07) 
4.74 (1.94 - 11.56) 
0.52 (0.36 - 0.74) 
0.54 (0.38 - 0.78) 
Aβ42 + phospho-tau 93.3% 
56 / 60 
89.1% 
41 / 46 
48.5% 
16 / 33 
81.3% 
113 / 139 
7.27 (2.65 - 19.97) 
4.46 (1.81 - 10.96) 
0.55 (0.39 - 0.77) 
0.58 (0.41 - 0.82) 
HC atrophy  61.5% 
8 / 13 
87.5% 
7 / 8 
71.4% 
15 / 21 
NA* 
2.28 (1.09 - 4.75) 
NA* 
0.20 (0.03 - 1.34) 
Data presented as percentage and correctly allocated subjects of all subjects in the group or 
as LR (95% CI). The table also includes these figures of MTL atrophy (at least one of the HC 
was atrophied) of the 21 patients from study IV. The first LR indicates the results when 
progressive MCI patients were compared to controls and the second LR indicates the results 
when the progressive MCI patients were compared to stable MCI patients. LR, likelihood 
ratio, MCI, mild cognitive impairment. *NA not applicable. 
 
The amnestic MCI and executive MCI patients were over 10 times more likely to develop 
dementia than patients with other types of cognitive impairment.(Figure 4) There was no 
significant difference in progression to dementia between the amnestic MCI patients and 
executive MCI patients. 
 
All of the studied CSF biomarkers were significant predictors of dementia alone, but in the 
backward logistic regression CSF tau was the only biomarker that remained significant. In 
order to obtain more reliable results on the predictivity of the CSF biomarkers for 
development of dementia, the survival analysis of MCI patients with different numbers of 
abnormal biomarker values (Aβ42 or tau) was conducted by including all of the patients from  
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Figure 4. The survival curves of 79 MCI patients divided into groups according to the type of 
their cognitive impairment. The end point event was the development of dementia. The solid 
line represents the patients with other types of cognitive decline, the dashed line represents 
amnestic MCI patients and the dotted line represents executive MCI patients. 
 
 
 
Figure 5. Survival curves of 80 MCI patients (79 from study III and one from study IV) 
divided into groups according to CSF Aβ42 and tau values. The end point event was the 
development of dementia. The solid line represents the patients with normal biomarker 
values, the dashed line represents patients with either abnormal Aβ42 of tau value and the 
dotted line represents patients with both abnormal Aβ42 and tau values. 
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study III and one additional patient from study IV. The follow-up period was also one to two 
years longer in eight stable MCI patients from study II. Figure 5 shows that MCI patients who 
have normal CSF biomarker values progress to dementia less frequently than those MCI 
patients who have either abnormal CSF levels of Aβ42 or tau. Almost all of the MCI patients 
who have both abnormal Aβ42 and tau develop dementia, over half of them during the first 
five years after the sample collection.  
 
5.6 ASSOCIATION BETWEEN CSF BIOMARKERS AND MEDIAL TEMPORAL 
LOBE ATROPHY 
In the whole study group, CSF tau levels correlated inversely with both right and left HC and 
volume of left EC. The results of phospho-tau were virtually identical. CSF Aβ42 correlated 
with the volume of left HC. When the groups were analysed separately, in the stable MCI 
patients tau correlated with volumes of both hippocampi and with left EC volume. The results 
of phospho-tau were otherwise similar, but the correlation with left EC did not reach 
statistical significance. In the progressive MCI patients, left HC volume correlated with CSF 
Aβ42 and phospho-tau. Word list delayed recall correlated positively with both right and left 
HC volumes and inversely with CSF tau and phospho-tau. In the subgroup analyses, there 
were no significant correlations in the stable MCI patients whereas there was a significant 
correlation between delayed recall and left hippocampal volume in the progressive MCI 
patients.  
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6. DISCUSSION 
 
6.1 CHANGES IN CSF Aβ42, TAU AND PHOSPHO-TAU OCCUR EARLY IN THE 
COURSE OF THE DISEASE 
Since the neuropathological changes of AD may start to develop as early as two decades 
before the onset of symptoms, we hypothesized that the AD associated changes in CSF 
biomarkers would be evident before the clinical diagnosis of AD and could be used to predict 
the development of AD in MCI patients. Based on the results of studies II and III, this 
hypothesis was proven to be true. CSF Aβ42 levels were decreased and CSF tau and phospho-
tau levels were increased in those MCI patients who received a diagnosis of AD during a 
follow-up period of approximately four years. It should be emphasized that these subjects 
could not be clinically separated from the stable MCI patients even though they underwent a 
thorough clinical and neuropsychological examination. The results indicate that the changes 
in CSF biomarkers are related to the presence of AD associated neuropathology in patients 
with progressing cognitive impairment before dementia. However, the variability in CSF 
biomarker levels between individual subjects in each group was large and there was a 
significant overlap between the groups. 
 
6.2 BIOLOGICAL VALIDITY OF CSF BIOMARKERS 
One of the most important criteria for a biomarker is that it should detect the fundamental 
feature of neuropathology of AD (Consensus report of the Working Group on: "Molecular 
and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research 
Institute of the Alzheimer's Association and the National Institute on Aging Working Group. 
1998). Previous studies in transgenic mice have suggested that the on-going amyloid 
pathology is reflected in plasma and CSF (DeMattos et al. 2002, Kawarabayashi et al. 2001). 
The results from study I on mice confirmed these findings. CSF Aβ42 levels in mice started 
to decline at the time when the progression of amyloid pathology accelerated in brain. 
Although it is not possible to directly extrapolate the results from the mice to human disease, 
these results imply that the amyloid plaques may well interfere with the clearance of Aβ42 
from brain to CSF. 
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Few human studies that have examined the association between CSF Aβ42, tau and phospho-
tau and AD neuropathology. One study examined post mortem ventricular CSF Aβ42 levels 
and found that lower levels correlated with amyloid pathology in brain and cerebral vessels 
(Strozyk et al. 2003). Other studies have shown that CSF tau or phospho-tau231 correlate 
with NFT score or levels of hyperphosphorylated tau in neocortex (Buerger et al. 2006a, 
Tapiola et al. 1997). One study on ante mortem CSF found that increased tau levels were 
associated with AD and decreased Aβ42 levels were associated with DLB and prion disease 
(Clark et al. 2003). However, the association was not assessed between the CSF biomarkers 
and quantitative amount of amyloid or tau pathology. One recent study examined the 
diagnostic accuracy of CSF Aβ42, tau and phospho-tau in 100 neuropathologically confirmed 
AD patients (Engelborghs et al. 2007). The CSF biomarkers helped to distinguish seven out of 
nine of those AD patients whose clinical diagnosis had remained uncertain. Again, CSF Aβ42 
levels were lower and tau and phospho-tau levels higher in the AD patients when compared to 
controls, but the association of the CSF biomarkers to the quantitative amount of pathology 
was not reported. Even though the current data is sparse, it seems that these biomarkers reflect 
AD associated neuropathological changes. Our own preliminary data from a large 
clinicopathological study supports this belief, the ante mortem biomarkers correlated with 
quantitative amyloid and NFT pathology in the neuropathological examination.  
 
Our own longitudinal study showed that the CSF Aβ42 levels decreased during a three year 
period, possibly reflecting the aggravation of the amyloid pathology in the brain (Tapiola et 
al. 2000b). Other human data support also the association between the CSF Aβ42 and 
amyloid pathology. Molecular imaging of amyloid using amyloid binding compound PIB in 
living subjects has been shown to reflect amyloid accumulation in the brain (Kemppainen et 
al. 2006). The reduced CSF Aβ levels are associated with increased PIB binding in brain, 
which supports the association of a decline in CSF Aβ42 levels and extent of amyloid 
pathology (Fagan et al. 2006). Furthermore, in a study combining CSF biomarkers and PIB 
analysis, all of the subjects whose CSF Aβ42 level was below 457 pg/ml displayed also 
positive PIB binding and those whose levels were above that level showed negative PIB 
binding (Fagan et al. 2007). This value is virtually the same as the calculated cut-off value for 
Aβ42 in study II. 
 
Thus the current data indicate that CSF biomarkers are strongly associated with the AD 
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associated neuropathology. However, the mechanisms involved in the development of CSF 
changes have remained unclear. Several mechanisms may influence CSF Aβ42 levels during 
the development of AD. The reduced levels may be due to the decreased synthesis, increased 
elimination or decreased clearance into CSF from the brain. Metabolism of Aβ42 is a very 
dynamic process. A recent study showed that Aβ42 is rapidly produced and cleared from the 
brain (Bateman et al. 2006). Therefore even very slight changes in the balance between the 
synthesis and elimination might lead to accumulation of amyloid in brain as plaques. Many 
studies, including our study III, have shown that the ApoE 4 allele has a dose dependent 
effect on CSF Aβ42 levels (Prince et al. 2004, Sunderland et al. 2004, Tapiola et al. 2000a). 
Furthermore, the CSF Aβ42 levels decrease faster over an average of a four year period in 
ApoE 4 positive subjects than in the ApoE 4 negative subjects (Huey et al. 2006). The 
association between the ApoE and neuropathology of AD is complex but the 
neuropathological studies have suggested that ApoE 4 can enhance Aβ aggregation (Gomez-
Isla et al. 1996, Moir et al. 1999, Polvikoski et al. 1995) which in turn might lead to decreased 
CSF Aβ levels. Recent data also indicate that CSF Aβ42 levels show an hour-to-hour 
variation within individuals, with the trend for increasing levels starting from morning 
(Bateman et al. 2007). The changes seem large enough to have possible implications on 
diagnostic use and may require standardization of protocols with respect to time for collecting 
CSF samples. 
 
6.3 CSF BIOMARKERS AS DIAGNOSTIC AIDS 
Our results revealed that the combination of decreased CSF Aβ42 and increased tau or 
phospho-tau predicted relatively accurately the development of AD during a follow-up of a 
few years. Another recent study also reported that the combination of CSF Aβ42 and tau was 
a good predictor of developing AD (Hansson et al. 2006). The high positive likelihood ratio 
(LR) indicates that the abnormal result in the combination test confirms AD in mildly 
impaired patients with high accuracy. Only 7% of the controls and 11% of the stable MCI 
patients who had both abnormal Aβ42 and tau did not develop dementia. However, these 
subjects may be false positives because it is impossible to exclude AD associated 
neuropathological changes even in clinically healthy controls, much less in the stable MCI 
patients. Many studies have shown that apparently asymptomatic subjects may display brain 
pathology that fulfils the neuropathological criteria for AD (Bennett et al. 2006, Galvin et al. 
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2005, Neuropathology Group. Medical Research Council Cognitive Function and Aging 
Study 2001, Price and Morris 1999). The lack of a golden standard, the neuropathological 
diagnosis, is a problem in most biomarker studies performed on living subjects. This may also 
result in low accuracy in the differentiation between AD and other dementias since AD 
pathology is a common finding in subjects with VaD and DLB (Holmes et al. 1999, Londos et 
al. 2001, Neuropathology Group. Medical Research Council Cognitive Function and Aging 
Study 2001). It is possible that changes in CSF Aβ42 and tau reflect the presence of 
neuropathology of AD in subjects that receive another clinical diagnosis. One way to improve 
the accuracy of the clinical diagnosis is to use a long follow-up. The one control subject who 
entered the study as a healthy control but was later excluded from study due to development 
of AD emphasizes this problem in cross-sectional studies. Her measured biomarkers were 
clearly abnormal at the stage when her cognitive capability was normal, but after ten years 
follow-up she developed AD. Also others have reported decreased CSF Aβ42 levels in 
cognitively healthy subjects who later developed AD (Skoog et al. 2003). Although the 
follow-up period in our study, approximately four years, was longer than in most of the 
previous MCI studies, it would need to be even longer to reliably exclude all patients with 
developing AD. Thus it is possible that our stable MCI group also includes a few patients who 
will ultimately progress to dementia. 
  
The present clinical criteria for AD date from 1993 and progress in both clinical and 
biomedical research has implications for revising the criteria. Currently, symptomatic 
medications for AD are widely used, but also disease modifying treatments are under 
development. Numerous compounds have entered preclinical studies and phase I and II 
clinical trials, and there are as many as twelve different compounds undergoing phase III 
trials for either slowing or attenuating the disease progression (Alzheimer Research Forum). 
Many of these compounds are drugs that are already in clinical use for other indications, for 
example statins and non-steroidal anti-inflammatory drugs (NSAIDs). Two of these test 
compounds may influence metabolism of Aβ. Tramiprosate (AlzhemedTM) binds to Aβ and 
prevents the formation of amyloid fibrils in transgenic mice (Alzheimer Research Forum). R-
flurbiprofen (FlurizanTM) belongs to the NSAID group, but it is the only member of that class 
of compounds that has proven effect on Aβ production since it selectively modulates γ-
secretase activity, decreasing the production of Aβ42 (Eriksen et al. 2003). Although the first 
Aβ vaccination trial was prematurately terminated due to side effects, less toxic Aβ 
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immunotherapeutic approaches are under development (Brendza and Holtzman 2006, Schenk 
2002, Senior 2002). It is likely that any disease modifying treatment would be most helpful if 
it could be initiated at an early stage of the disease. However, although the current clinical 
criteria work relatively well in advanced AD, they are not suitable for providing an early 
diagnosis. The discussion on updating the criteria is already underway wit the key objective 
being to improve the early diagnosis of AD. One issue in the debate is the role of CSF 
biomarkers and other paraclinical tests in AD diagnostics. Although there are still many 
unresolved issues in understanding the characteristics of CSF Aβ42 and tau, a knowledge of 
their levels may be helpful for clinicians. However, due to their low sensitivity, CSF 
biomarkers will only serve as a supportive test for positive diagnosis, not as a crucial part of 
the standard diagnostic criteria. 
 
6.4 ASSOCIATION BETWEEN CSF BIOMARKERS AND STRUCTURAL 
CHANGES IN MEDIAL TEMPORAL LOBE  
MTL atrophy has also been intensively evaluated as a possible biomarker for AD and several 
studies have shown that the presence of MTL atrophy predicts progression of MCI and 
development of AD (Bouwman et al. 2006, Jack et al. 1999, Killiany et al. 2000). Study IV 
showed that CSF biomarkers, especially tau and phospho-tau were significantly correlated 
with MTL atrophy. The data in the literature is sparse and contradictory. One study reported a 
significant relationship between CSF phospho-tau231 and HC volume in 22 AD patients, 
whereas another study on 88 patients found no correlation between these parameters (Hampel 
et al. 2005, Schonknecht et al. 2003). A study with 18 MCI patients and controls reported an 
inverse correlation between CSF phospho-tau231 and HC volume, whereas a positive 
correlation in AD patients was found in another study (Hampel et al. 2005, de Leon et al. 
2004). One recent study using a visual rating of MTL atrophy instead of volumetric analysis 
reported an inverse relationship between MTL atrophy and CSF Aβ42, but no correlation to 
CSF tau in 39 MCI patients (Schoonenboom et al. 2005). The data from study IV should be 
considered very cautiously due to the small sample size. However, it is intriguing, that CSF 
tau levels correlated with MTL atrophy. CSF tau has been suggested to represent a marker for 
axonal and neuronal damage (Blennow et al. 1995). It is possible that CSF tau reflects the rate 
of neuronal cell death and axonal damage predominantly in MTL structures, which would fit 
well to the model of progression of NFT pathology in AD (Braak and Braak 1991). Another 
possibility is that the correlation arises from the presence of AD per se since both markers 
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reflect the disease. 
 
In conclusion, these studies support the hypothesis that CSF tau may reflect 
neurodegeneration in AD. However, the number of patients in the studies is small and thus it 
is not possible to examine the added value of each of these biomarkers in the diagnosis of AD. 
 
6.5 CLINICAL IMPLICATIONS  
In addition to having devastating effects on life of the individual patients and their families, 
AD also poses enormous socioeconomic burden the society. It is estimated that in 2005 there 
were over 29 million people who had dementia and worldwide societal costs were US$ 315 
billion, over US$ 100 billion in European Union alone (Wimo et al. 2007). As the population 
ages, the number of patients and costs of care will increase even further. The undiagnosed AD 
patient is more expensive for society than the patient with a diagnosis and appropriate 
treatment (Hill et al. 2002). Therefore it is essential to detect the AD patients as early as 
possible out of the vast pool of patients who may express concern about cognitive 
impairment. Predicting the prognosis of MCI based on neuropsychological features is not 
possible without follow-up examinations to reveal a decline. Progression to AD and other 
dementias varies greatly between studies due to different definitions of MCI, differences in 
populations studied and length of the follow-up period. Therefore, the design of this study 
was practical, based on a "real life" situation. The majority of the subjects were recruited from 
the memory clinic and the inclusion criteria were intentionally relatively wide. The MCI was 
not defined according to strict criteria of amnestic MCI but also patients with declines in other 
cognitive domains were included. Nonetheless, a detailed assessment of several cognitive 
domains was performed, and the effect of the type of cognitive impairment on progression 
was also examined. 
 
Many studies have shown that the most consistent predictor for AD and other dementias is 
memory performance during a long follow-up. AD patients exhibit problems in both visual 
and verbal memory as early as ten years before the onset of dementia (Elias et al. 2000, 
Kawas et al. 2003, Tierney et al. 2005). The decline in other cognitive domains including 
fluency, speed and attention becomes apparent closer to the diagnosis (Saxton et al. 2004, 
Tierney et al. 2005). Studies with a short follow-up period have shown inconsistent results. 
Some studies have found that the amnestic symptoms are the best indicators for predicting 
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dementia (Busse et al. 2003, DeCarli et al. 2004, Perri et al. 2007). On the contrary, the 
predictive value of amnestic symptoms has been poor in many studies and patients with 
isolated memory impairment have shown low rates of progression to dementia (Bozoki et al. 
2001, Meyer et al. 2002a, Sacuiu et al. 2005). A significant number of patients even improve 
during the follow-up (Ganguli et al. 2004). Furthermore, individual amnestic MCI patients 
progress to dementia with very distinct patterns of cognitive decline. It seems that the rate of 
progression varies and cognitive domains are affected in a different order (Hodges et al. 
2006). 
 
The results of study III indicated that executive MCI was frequent and these patients 
progressed to dementia even faster than amnestic MCI patients. This is probably due to the 
fact that a large proportion of the MCI patients was derived from the clinic and therefore 
might have been closer to the dementia stage of AD at the baseline. The progression rate to 
dementia was 51% in the amnestic MCI patients and 41% in the executive MCI patients. 
However, it needs to be noted that the follow-up period of the stable amnestic MCI patients 
was two years shorter than that of the executive MCI patients. Therefore the difference in 
progression rates to dementia might be higher if the amnestic MCI patients were followed as 
long as the executive MCI patients. Executive dysfunction has emerged as possible predictor 
of dementia also in other studies. Executive dysfunction is a common comorbidity factor in 
amnestic MCI patients (Loewenstein et al. 2006, Nordlund et al. 2005) and it may occur on its 
own without amnestic symptoms, as in our study (Royall et al. 2004, Tabert et al. 2006). 
Amnestic MCI patients with concomitant executive dysfunction also convert to dementia at 
higher a rate than patients with isolated amnestic symptoms (DeCarli et al. 2004). 
 
The rarity of isolated amnestic MCI suggests that in the clinical setting the patients who 
complain of cognitive problems other than memory disturbance should also be considered to 
be at high risk for dementia, particularly AD. The high frequency of executive MCI without 
amnestic symptoms in this study and the high progression rate to dementia of these patients 
strongly supports this belief. It has also been suggested that executive dysfunction influences 
the activities of daily living and thus the development of the full-blown dementia syndrome 
more than memory decline (Royall et al. 2005). Furthermore, almost half of the subjects who 
develop dementia within a three year period do not report memory problems in the clinic even 
when they are asked directly (Palmer et al. 2003). Therefore the amnestic MCI criteria 
exclude a high number of MCI patients who are at a high risk of developing AD and other 
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dementias. In summary, clinicians should not concentrate only on memory impairment in 
their evaluation of the predementia stage of AD. Nonetheless, it seems that even the most 
detailed single neuropsychological assessment cannot distinguish MCI patients who will 
develop dementia from those who will remain unchanged. Also, the causes of executive MCI 
may be more heterogeneous than those of amnestic MCI. Therefore one will need to resort to 
other diagnostic instruments such as CSF biomarkers are when trying to clarify the diagnosis 
and prognosis of the typical MCI patient.  
 
6.6 LIMITATIONS OF THE STUDY 
The study population of this study included subjects from both a population based cohort and 
from the memory clinic. Therefore the neuropsychological tests that were used for assessing 
different cognitive domains, especially memory, varied between different patients. However, 
the normative values for the different memory tests were available. The inclusion of subjects 
from the memory clinic may lead to a potential selection bias. Although all patients with 
cognitive complaints were invited to participate in the study, many declined and it is possible 
that those with more severe symptoms were more willing to enter the study. Also the 
inclusion of patients with depression may be problematic. Many behavioural symptoms, 
especially depression, may precede memory impairment and dementia years before the onset 
of symptoms. Therefore it is possible that the control group included a few patients who may 
eventually progress to MCI and dementia. The etiology of MCI was not defined in large 
proportion of stable MCI patients. This may be partly due to the fact that most patients 
underwent CT imaging instead of MRI and therefore mild atrophy or vascular pathology 
could not be detected. Thus, many of the stable MCI patients may have been suffering from 
VCI. It is also impossible to exclude mild depression or temporary use of some medication 
that could slightly impair cognitive function. Furthermore, when the study was initiated, the 
criteria for MCI included the cognitive impairment beyond age-adjusted normative values, not 
impairment over a period of time. Thus, some stable MCI patients may have had a low basic 
level of cognitive functions for all their lives but the values would low enough that they were 
included in the study. The follow-up period was longer than in most previous studies, but an 
even longer time would be needed to reliably detect all patients who will eventually develop 
AD. Also, the final diagnosis of AD was based on clinical criteria, and no neuropathological 
confirmation of the diagnosis was undertaken. Although the number of studied subjects was 
quite substantial, it is too small to accurately assess the added value of CSF biomarkers as 
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diagnostic tests for AD. 
 
There are also some methodological limitations. Considering the recent data on hour-to-hour 
variability of CSF Aβ42 values within the same individual, (Bateman et al. 2007) one 
possible limitation of this study is that the time of the CSF sampling was not standardized. 
The CSF samples were collected mainly at midday or in the early afternoon, which is also the 
time that out-patient clinic CSF samples are taken in general. The standard polypropylene 
tubes were used to prevent the artefactually low Aβ42 level due to binding to the tubes. The 
samples were immediately aliquoted and frozen, and they were stored at -70°C until analyses. 
Some of the samples were frozen for up to a decade but no association between the storage 
time and CSF Aβ42, tau and phospho-tau was detected. The intra-assay variation was not 
assessed during the study. However, these assays are currently provided as a diagnostic 
service and run routinely in the same department where the study was conducted. The long 
term variability has remained good, median intra-assay CV% being 14.6% for Aβ42, 8.3% for 
tau and 6.7% for phospho-tau. 
 
In the context of the studies on mice it needs to be taken into account that the physiology of 
the mouse is different from the human and the results of these studies cannot be extrapolated 
to humans directly. The transgenic mice are even further divergent from humans, because 
their normal physiology is disturbed by the inclusion of two genes with different mutations. 
The resulting changes in different studied parameters are most likely due to the influence of 
these inserted genes, but it is also possible that the transgene construct is inserted in a way 
that it disturbs the function of some endogenous gene. However, both of the mouse lines that 
were used in this study have been well characterized, and the development of amyloid 
pathology as a result of the mutated APP and PS1 genes has been described in numerous other 
transgenic mouse lines as well (Borchelt et al. 1997, Jankowsky et al. 2004, Spires and 
Hyman 2005). The development of amyloid pathology in mice is different from the 
neuropathological process in human brains. In transgenic mice, the main reason for Aβ 
accumulation is the increased production of Aβ, whereas in human brain, especially in 
sporadic AD, the accumulation is a consequence of several factors, including decreased 
degradation and reduced clearance of Aβ. Furthermore, the mice do not exhibit abundant 
vascular amyloid pathology or age related changes in brain. It could be speculated that these 
common changes including atherosclerosis, are also important contributors to the 
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neurodegenerative process in humans but are not present in the mouse models. The amyloid 
pathology also develops very rapidly in the mice, during a 6-month time frame, whereas in 
humans the pathology appears over a period as long as two decades. Another limitation of the 
mice that were used in this study is the fact that they do not develop tau pathology. Therefore 
the study examined only the association between the CSF Aβ42 and amyloid pathology in 
these mice. However, the results of study I supported the data on human studies; the CSF 
Aβ42 levels decreased simultaneously with the increasing amyloid pathology. 
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7. CONCLUSIONS 
The aim of the present study was to investigate whether the CSF Aβ42, tau and phospho-tau 
can be used as diagnostic aid in diagnosis of early AD. The secondary aim was to examine the 
relationship between the CSF biomarkers and neuropathological processes associated with 
AD. The following conclusions can be drawn: 
 
1. AD associated changes in CSF biomarkers, i.e. decrease in Aβ42 and increase in tau 
and phospho-tau occur during a predementia stage of AD. 
 
2. CSF Aβ42, tau and phospho-tau values are associated with MTL atrophy. CSF tau 
levels may reflect the neuronal damage occurring in MTL. 
 
3. ApoE 4 allele has a dose dependent effect on CSF biomarkers such that the Aβ42 
levels decrease and tau and phospho-tau levels increase with elevating numbers of 
ApoE 4 alleles. 
 
4. A large proportion of MCI patients do not have memory impairment. Executive 
dysfunction without amnestic symptoms is common, and many of these patients 
progress to AD. In the clinical context, patients with cognitive impairment without 
memory complaint should be also considered to be at a high risk for developing AD. 
 
5. Several years before the any clinical diagnosis can possibly be made, the combination 
of decreased CSF Aβ42 and increased tau or phospho-tau can differentiate with high 
specificity those MCI patients who will eventually develop AD from those who 
remain stable. The positive test result can be used as a confirmation of a clinical 
diagnosis of possible early AD. However, the sensitivity of the test is low and a 
negative result cannot exclude the presence of AD. 
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